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RÉSUMÉ  
Exposé de la situation : Des études menées sur les animaux démontrent que  le 
système endocannabinoide est important dans le maintien de l’homéostasie de 
l’énergie et que les effets de sa modulation sont différents selon le sexe et 
l’exposition à la nicotine. Deux études longitudinales ont étudié l’association entre 
l’usage du cannabis (UC) et le changement de poids et ont obtenus des résultats 
contradictoires. L’objectif de ce mémoire est de décrire la modification de 
l’association entre l’UC et le changement de poids par la cigarette chez les jeunes 
hommes et femmes.   
Méthodes : Des donnés de 271 hommes et 319 femmes ont été obtenues dans le 
cadre de l’étude NICO, une cohorte prospective (1999-2013). L’indice de masse 
corporelle (IMC) et la circonférence de taille (CT) ont été mesurés à l’âge de 17 et 25 
ans. L’UC dans la dernière année et de cigarette dans les derniers trois mois ont été 
auto-rapportées à 21 ans. Les associations entre l’UC et le changement d’IMC et de 
CT ont été modélisées dans une régression polynomiale stratifiée par sexe avec 
ajustement pour l’activité physique, la sédentarité et la consommation d’alcool. 
Résultats : Uniquement, chez les hommes, l’interaction de l’UC et cigarettes  était 
statistiquement significative dans le model de changement IMC (p=0.004) et celui de 
changement de CT (p=0.043). L’UC était associé au changement d’adiposité dans 
une association en forme de U chez les homes non-fumeurs et chez les femmes, et 
dans une association en forme de U-inversé chez les hommes fumeurs.  
Conclusion :  La cigarette semble modifier l’effet du cannabis sur le changement 
d’IMC et CT chez les hommes, mais pas chez les femme.  
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ABSTRACT  
Background: Animal studies suggest that the endocannabinoid system is a regulator 
of energy homeostasis, whose effects are modified by sex and nicotine. Two studies 
in humans have examined the association between cannabis use and change in 
adiposity, and obtained conflicting results. This thesis aimed to determine if the 
association between cannabis use and change in adiposity is modified by cigarette 
smoking in young adults. 
Methods: Data were available for 271 males and 319 females participating in the 
Nicotine Dependence In Teens study, a prospective cohort investigation (1999-2013). 
Body mass index (BMI) and waist circumference (WC) were measured at ages 17 
and 25 years. Self-report data on past-year cannabis use and past three-month 
cigarette smoking were collected at age 21 years. Modification of the association 
between cannabis use and change in adiposity by cigarette smoking was tested 
separately in each sex, in polynomial linear regression models controlling for 
physical activity and sedentary behavior in both sexes, and alcohol use in males only. 
Results: In males only, the interaction between cannabis use and cigarette smoking 
was statistically significant in both the model for change in BMI (p=0.004) and the 
model for change in WC (p=0.043). Cannabis use was associated with change in 
adiposity in a U-shaped form in females and in non smoking males, and in an 
inverted U-shaped association in males who smoked more than 10 cigarettes per day. 
Conclusion:  Smoking cigarettes appears to attenuate the association between 
cannabis use and change in adiposity in young men, but not in young women. 
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 Chapter 1: Introduction 
The ongoing obesity epidemic is of considerable concern worldwide. In 
Canada, 62% of the population is overweight or obese and the healthcare burden 
associated with overweight is estimated at $4.3 billion annually in direct and indirect 
costs (1, 2). These conditions are associated with numerous health problems 
including diabetes and cardiovascular disease (3).  
Extensive research has identified a variety of risk factors for excess body 
weight  including sedentary behavior, physical inactivity, poor diet, and alcohol use, 
all of which have been targeted for preventive intervention (4-7). One of the targets 
of pharmaceutical weight loss interventions is the endocannabinoid system (ECS) (8). 
The ECS consists of several endogenous ligands called endocannabinoids, as well as 
many receptors that are found throughout the body including on cells in the central 
nervous system, the gastrointestinal tract, the liver, adipose tissue, the endocrine 
pancreas, immune and hepatic cells and skeletal muscle cells (9). The ECS is 
implicated in a plethora of physiological pathways through its signaling molecule and 
receptors, which include the cannabinoid-1 (CB1) and cannabinoid-2 (CB2) receptors 
(9).  
Because of interaction with the sex hormones, ECS action differs according to 
sex at the cellular level as well as at the endocrine level (10-12). The homeostatic 
effects of the ECS are more extreme in men, while its effects on mood, particularly 
anxiety, are more extreme in women (10). Many synthetic cannabinoids have been 
created for their clinical potential to decrease weight, modulate pain, and decrease 
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nausea, and pharmacological studies continue to explore the potential of the ECS (13, 
14). 
Of particular interest in this thesis is the role of the ECS in the maintenance of 
energy homeostasis through regulation of processes including appetite, lipogenesis 
and glucose uptake (14). The synthetic cannabinoid, rimonabant, was created to 
promote weight loss by acting antagonistically on the CB1 and CB2 receptors and 
down-regulating the ECS (13, 15). When taken regularly, rimonabant resulted in 
sustained weight loss independent of diet in obese patients, particularly among men, 
and interestingly, facilitated smoking cessation (12, 15). However, its psychiatric side 
effects prevented its introduction to the market. The decrease in weight resulting 
from inactivation of the CB1 receptor by antagonists underscores the importance of 
the ECS in energy homeostasis. In fact, the ECS has an impact on virtually every 
aspect of the metabolic syndrome (16).  
Cannabis is the most widely used illicit drug in the world (although it is not 
illicit in every country) with an estimated 125 to 203 million users in 2009 (17). The 
natural cannabinoid that first led to the identification of the CB1 receptor, was delta-
9-tetrahydrocannabinol (THC), the active component of the cannabis sativa plant, 
which acts agonistically on the CB1 receptor (18). Its immediate effect on appetite is 
well known and synthetic derivatives of THC are used for their orexigenic effect in 
patients suffering from cancer-related anorexia and acquired immune deficiency 
syndrome (AIDS) (14, 16). When used recreationally, cannabis is smoked and often 
co-used or used simultaneously with tobacco (19). Among U.S. cannabis users, 90% 
reported having been a cigarette smoker (19). Human and animal studies examining 
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the joint effects of cigarette and cannabis use have identified cigarette smoking as an 
important effect modifier of the action of THC on the ECS (20). Given that cannabis 
stimulates the ECS and over-activation of the ECS is observed in overweight and 
obese individuals, it is possible that cannabis use leads to weight gain, but that this 
effect is modified by cigarette smoking.  
To date, epidemiological studies that report on the association between 
cannabis use and weight are inconclusive (4, 21-25).  However, most of these studies 
did not consider sex differences and none examined possible effect modification by 
cigarette smoking. In this current study, we investigated the association between 
cannabis use and weight change longitudinally and we tested if the association is 
moderated by cigarette smoking. Because the literature suggests that the association 
of interest may be substantively different in males and females, we investigated these 
issues in males and females separately. 
 Chapter 2: Literature Review 
2.1.The biological framework of this study: the endocannabinoid system 
2.1.1. Components of the endocannabinoid system 
The ECS is a regulatory system formed of cannabinoid receptors, 
endocannabinoids and enzymes for their synthesis and inactivation (16). Among 
many receptors in the ECS, are two G-protein coupled receptors, CB1 and CB2 (8). 
The initial discovery of the ECS was made when the CB1 receptor was identified as 
the receptor activated by delta-9-tetrahydrocannabinol (THC), the active ingredient 
most highly present in cannabis (18). CB1 receptors are primarily located in the 
central nervous system (CNS) in the hypothalamus, the brainstem, the cerebral cortex 
and the mesolimbic dopaminergic system (16). These areas of the brain are 
responsible for energy regulation, feeding behaviors and reward circuits. CB1 
receptors have also been found in peripheral tissue including in the gastrointestinal 
tract, liver, adipose tissue, endocrine pancreas and skeletal muscles (9, 16). CB2 
receptors have been discovered in peripheral tissue including adipose tissue, skeletal 
muscle and the endocrine pancreas, where they act at the level of immune and 
hematopoietic cells to modulate the immune response (8). They are also located in 
the CNS where they act on cell proliferation, although their role remains 
controversial (26).   
 CB1 and CB2 receptors are activated by endogenous ligands called 
endocannabinoids. Since endocannabinoids are lipophilic, they are not stored in 
vesicles, but are formed on demand by the cell from phospholipid membrane 
precursors. Once released, these molecules act locally on the cell that produced them 
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or its neighboring cells. The two most common endocannabinoids are 
arachidonylethanolamide (anandamide, AEA), and 2-arachidonoylglycerol (2-AG) 
(9). Once bound to their receptors, the signaling molecules are enzymatically 
degraded within the cell by catabolic enzymes such as fatty acid amide hydrolase 
(FAAH) and monoacylglycerol lipase (MGL) (27). Multiple enzymes in complex 
cascades are involved in the synthesis and degradation of endocannabinoids. Adding 
to the complexity of these anabolic and catabolic cascades are enzymes that alter 
endocannabinoid signaling by enhancing reuptake or inhibiting degradation, thus 
modulating the intensity of endocannabinoid signaling (16).  
2.1.2. Role in energy homeostasis  
The multiple possible regulatory points in the ECS make it ideal for homeostatic 
control. Its activity can be altered or fine-tuned before, during or after synthesis and 
degradation of endocannabinoids and its efficiency can be modified through the 
density of its receptors and the creation of enhancing and inhibiting molecules. The 
widespread presence of the ECS throughout the human body and its extreme 
flexibility suggest an important role in maintenance of the homeostasis of many 
physiological processes. The ECS is implicated in suppression of aversive memory, 
motivation to eat, perceived palatability of food, creation of a stress response and 
emotional regulation through its receptors in the CNS (9, 28, 29). The ECS is also a 
key player in virtually every aspect of the metabolic syndrome through its peripheral 
receptors. These include insulin sensitivity, glucose uptake, fat deposition, regulation 
of appetite hormones, hypertension, cardiovascular disease, atherosclerosis, systemic 
inflammation and permeability of the gut (13, 14, 30). The role of the ECS in the 
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hypothalamus, its interaction with the hormones leptin and ghrelin, and its actions on 
certain peripheral organs will be described more fully in the context of energy 
homeostasis. 
CB1 receptors are present and endocannabinoids are produced in the 
hypothalamus region of the brain. More specifically they are found in the 
hypothalamic melanocortin system, which is formed of the arcuate (ARC) and 
paraventricular nucleus (PVN) (31). Overall this system regulates the stress response, 
feeding behavior and weight gain through secondary signaling molecules such as pro-
opiomelanocortin (POMC) pro-hormones. Within the ARC, endocannabinoids 
regulate feeding and body weight via neuropeptide Y (NPY), which when released, 
acts to increase feeding and produce weight gain. The endocannabinoids within the 
PVN along with corticotropin-releasing hormone (CRH) take part in regulation of 
energy homeostasis and in mediation of the stress response (29). Finally, it has been 
demonstrated that throughout various areas of the hypothalamus, endocannabinoid 
levels increase during fasting and decrease during feeding (14).  
In order to regulate energy homeostasis, the ECS must receive feedback signaling 
from periphery systems. Leptin is one such signal that is produced by adipose tissue. 
It has an inhibitory effect on the production of endocannabinoids in the hypothalamus 
(29, 32). Thus, with the accumulation of adipose tissue, there is an increase in leptin 
production, which in turn acts to inhibit the orexigenic effects of the ECS in the 
hypothalamus and decrease feeding and weight production.  
Another hormone involved in digestion is ghrelin, which also plays a similar role 
as the one proposed for endocannabinoids in feeding behaviors and weight gain. For 
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this reason their possible interaction has been of scientific interest. It has been 
suggested that they interact in a feed-forward manner (29). The production of ghrelin 
peripherally raises the levels of endocannabinoids in the hypothalamus, which in turn 
raise peripheral levels of ghrelin (9). The end result of this interaction is stimulation 
of feeding and energy storage.  
Until 2003, cannabinoid receptors were thought to be located in the CNS only. In 
2003, CB1 receptors were found in white adipose tissue, which triggered extensive 
research into their presence in peripheral tissues where they take part in local fine-
tuning of systemic energy regulation (33, 34). In adipose tissue, the ECS promotes 
adipogenesis through adipocyte differentiation and increased enzyme expression and 
activity (29). Increased activity of the ECS is positively correlated with increased fat 
mass (35). For example, FAAH activity, an enzyme that degrades endocannabinoids, 
increases with increasing BMI and waist circumference (WC) in humans (27). 
Furthermore, the expression of CB1 receptors increases in obese individuals 
compared to non-obese individuals, and in visceral fat compared to subcutaneous fat 
in obese individuals (9). It was recently demonstrated in humans that insulin down-
regulates the action of endocannabinoids in adipocytes (29). However, in insulin-
resistant adipocytes, such as in type 2 diabetic individuals, insulin is not capable of 
down-regulating the endocannabinoid activity responsible for fat deposition (35). 
 Given the role of insulin in the regulation of endocannabinoids, it is not 
surprising that the ECS also acts in skeletal muscles to modulate glucose uptake (14). 
In animal studies, CB1 and CB2 receptors have been found in liver cells, where they 
are thought to have role in the expression of lipogenic genes (8, 14).  
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2.1.3. Reward circuits of the ECS  
As described earlier, cannabinoid receptors are present in regions of the brain 
involved in reward circuits. More specifically, they can be found in the mesolimbic 
system where the ECS fine-tunes the reward response (28). The mesolimbic system is 
formed of several structures in the brain that create a pathway leading from the 
ventral tegmental area through the medial forebrain bundle to the striatum (28). This 
reward circuitry plays an important role in the motivation for and perception of 
“liking” aspects of behaviors such as feeding, sex and social interactions (16, 29). It 
controls behavior by inducing pleasurable effects, mainly through the release of 
dopamine, the “pleasure chemical” of the brain, within the nucleus accumbens (28). 
Notably, it is via this circuitry that the ECS influences palatability of food and food 
intake (16). The ECS is also ideally positioned to modulate the motivational and 
addictive effects of drugs of abuse. In animal studies, CB1 deletion diminishes the 
reinforcement of most drug classes (36). In human studies, administration of a CB1 
antagonist diminishes self-administration of alcohol, opioids and nicotine (36).  
2.1.4. Exogenous ligands: cannabis and synthetic antagonists 
Exogenous ligands, such as cannabis and synthetic antagonists, have played an 
important role in developing our understanding of the ECS and will be discussed in 
the following section. As mentioned previously, the ECS was initially discovered 
through its activation by THC, the active ingredient of the Cannabis Sativa plant 
(18). Cannabis can be found in the forms of marijuana, hash or hash oils. These 
forms differ in their concentration of THC and their plant constituents. Marijuana 
contains the dried flowers and leaves of the plant and has the lowest concentration of 
THC of the three forms. Hash consists of the resin of the plant that is collected and 
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compressed. Finally, hash oil is made from extraction of the resin from the plant (37). 
The psychoactive ingredient that is present in the highest quantity in cannabis is 
THC, which is responsible for the euphoria achieved during its recreational use. The 
acute effects of THC include, but are not limited to, increased hunger, impaired 
reaction time, increased heart rate, decreased blood pressure, impaired cognitive 
functioning including short-term memory and executive functioning, and altered 
sensorial function and emotional state (18, 37, 38).  
In addition to THC, the Cannabis sativa plant contains approximately 60 other 
cannabinoids. Notably cannabidiol has emerged as a compound with great 
therapeutic potential (13). It has low binding affinity for CB1 and CB2 receptors and, 
in contrast to THC, is non-psychotropic with anxiolytic, anti-addictive and 
antipsychotic properties which may serve in the treatment of neuropsychiatric 
disorders (18, 28, 39).   
In 1994, the first selective antagonist for the CB1 receptor, rimonabant 
(SR141716), was created (18). In a double-blind randomized clinical trial, 
rimonabant showed promising results for the treatment of the metabolic syndrome. 
Obese individuals who were administered 20 mg of rimonabant daily demonstrated 
weight loss, decrease in WC, improved lipid profiles, decrease in fatty liver and 
improved glucose control in diabetic individuals (15). It was also effective in 
treatment of nicotine dependence (20). Adverse psychiatric effects including suicide 
ideation resulted in its discontinuation, although many other selective antagonists, 
inverse agonists and neutral antagonists have since been created (15, 16).   
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2.1.5. Sex differences in the endocannabinoid system 
Researchers have recently begun to report important sex differences in the 
functioning of the ECS that may be relevant to energy homeostasis and weight 
changes.  Advances in this area have been outlined in three literature reviews, which 
synthesized the results of biological, pharmacological and behavioral studies in 
animals and humans (10-12). It has been reported that men consume greater amounts 
of cannabis and at a greater rate than women (12). However, women have higher 
activity levels of the enzymes required to metabolize THC into its bioactive form, 11-
hydroxy-THC (10). Men demonstrate higher levels of circulating THC, more 
withdrawal symptoms and they are more sensitive to the hyperphagic and hypophagic 
effects of cannabis and the CB1 antagonist respectively (12). Men may be more 
susceptible to the cognitive consequences of cannabis use such as decreased memory 
and increased risk of psychosis (11). Women with poor mental health are more at risk 
than other women of using cannabis as well as at increased risk of depression as a 
result of cannabis use, which is not the case in men (12, 40).    
Female rodents are more sensitive to the down-regulating effect of leptin on 
endocannabinoids than male rodents (10).  Important differences have also been 
reported in animal studies at the POMC synapses, which are involved in stress 
response, feeding behavior and weight gain (10). These synapses have been shown to 
potentiate differently in male and female animals with CB1 activation resulting in 
increased excitation in females and in inhibition in males (10). Finally, the 
functioning of the ECS differs by sex as a result of its interaction with gonadal 
hormones. In females, the density of the CB1 receptor varies with the oestrous cycle, 
and therefore, females are most sensitive to the effects of THC in oestrous phase (10, 
12 
12). In females, increases in POMC is dependent on estrogen (10). Finally, in males, 
increases induced by THC in CRH (a hormone in involved in the regulation of the 
stress response) are dependent on dihydrotestosterone. The three reviews all suggest 
that these sex differences should be taken into account in future research (10-12).  
2.2.Obesity  
2.2.1. Definition 
Overweight and obesity are complex multifactorial conditions that are the subject 
of much current research. On a fundamental level, they result from an energy intake 
that exceeds energy expenditure. High energy intake is the result of consuming foods 
high in fat, sugars and salt, but low in nutritional value from vitamins, micronutrients 
and minerals (3). Low energy expenditure results from low levels of physical activity 
and high levels of sedentary behavior (41). Obesity and overweight categories are 
often defined by body mass index (BMI) values which are calculated by weight in 
kilograms divided by height in meters squared (kg/m
2
). The World Health 
Organization (WHO) definitions for overweight and obesity are a BMI ≥25 and ≥30, 
respectively (3). The main health problems related to overweight are an increased 
risk of cardiovascular diseases, diabetes, musculoskeletal disorders and certain 
cancers, which together result in 2.8 million adult deaths each year (3).  
 Although the use of BMI as a marker for heightened health risk is 
widespread, controversy remains as to whether or not it is the most appropriate 
indicator of high risk (42). An alternate measure is waist circumference (WC), which 
has been proposed as a better indicator of increased cardiometabolic risk since, it 
indicates the inability of the body to cope with the excess energy storage (42). This 
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results in fat deposition in the liver, heart, skeletal muscle and visceral adipose tissue 
(42).  
2.2.2. Trends in obesity 
Although obesity rates have been rising since the beginning of the last century, it 
was not until 1997 that the WHO recognized obesity as a global epidemic (41). 
Obesity rates throughout the world have more than doubled since the 1980s (41). In 
2008, there were more than 1.4 billion adults who were overweight, 200 million of 
whom were obese (3). In Canada in 2008, 62% of the population had a BMI greater 
than normal and  25% were obese based on measured height and weight (2). The 
prevalence of obesity increases with age until age 65, at which point it decreases (2). 
Among Canadian youth aged 2 to 17 years, the prevalence of obesity was 26% in 
2004, an 11% increase since 1979 (43). The prevalence of obesity and overweight 
varies by region. In Canada, the lowest prevalence is observed in British Columbia 
(13%) and the highest in Newfoundland and Labrador (25%) (2). In Quebec, the self-
reported prevalence of obesity is 16% and in Montreal, it is 13% (2). The cost to the 
health care system of obesity was estimated at 4.6 billion in Canada in 2008 (2).  
2.2.3. Factors associated with overweight 
Above normal BMI varies by age, sex, language and ethnicity, socio-economic 
status, physical activity, sedentary behavior, diet, alcohol use, mental health and 
smoking status (44).  Further, potential determinants of obesity vary by age, sex and 
ethnicity (2, 45). In the following section, each of these potential determinants is 
discussed briefly and, where possible, their applicability to the Quebec or Canadian 
young adult population will be described according to sex.  
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As previously outlined, the prevalence of overweight and obesity increases with 
age up until the age of 65 years in Canada, after which it declines (2). Generally, high 
BMI is more prevalent in males than females (2, 44). This is true for the region of 
Montreal, where 59% of adult men and 40% of adult women are overweight or obese 
(46). Obesity and overweight also vary by ethnicity and immigration status (47). 
Recent immigrants have a lower prevalence of obesity compared to those who 
immigrated more than 10 years prior (47). Finally, within the province of Quebec, 
speaking a language other than French is associated with overweight and obesity in 
women (45).  
 Factors affecting energy output including physical activity and sedentary 
behavior are also associated with overweight. There is a lower prevalence of physical 
activity among overweight and obese men and women, although the prospective 
nature of this association remains controversial (5, 7, 43, 48). Individuals who are 
overweight and obese are more likely to engage in sedentary behaviors such as 
watching television, playing games or working on the web, playing video games, and 
reading (2, 5, 7).  
Factors affecting energy intake directly are diet and alcohol consumption. The 
frequency of eating home-made meals, eating in fast food restaurants, exposure to 
food marketing and food insecurity all influence diet quality (2, 5). The association 
between alcohol use and excess weight is more pronounced in men than in women 
(2). Moderate alcohol intake is negatively associated with excess weight, while high 
alcohol intake is positively associated with excess weight in both sexes (6). Further, 
this association varies depending on the type of alcoholic beverage consumed; spirits 
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and beer are associated with increased weight, while wine is associated with 
decreased weight (6). Finally, overweight and obese men and women are at a 
decreased risk of alcohol and drug abuse (49). A possible explanation for this 
association is competing neuronal reward pathways within the brain (49). 
 Smoking influences energy intake through the effect of nicotine, which 
decreases appetite and increases metabolic rate (20). Smoking cessation is thought to 
result in increased appetite and food intake (20). Smoking is more prevalent among 
the overweight and obese possibly because of clustering of unhealthy behaviors or 
because of the known weight loss effects of smoking, particularly in women (50-52).  
Finally, overweight and obesity are associated with major depression, bipolar 
disorder, anxiety disorder, schizophrenia and substance abuse disorders (49, 53-55). 
A positive bidirectional relationship is observed between above normal BMI and 
major depression (56, 57). Bipolar disorder and anxiety disorders are more prevalent 
among the overweight and obese, although the direction of the relationship is not 
clear (54, 56). Lastly, individuals with schizophrenia are more likely to have the 
metabolic syndrome (55).  
2.3. Cannabis use  
2.3.1. Trends in cannabis use 
Globally 3-5% of individuals consume cannabis each year which, according to 
the WHO, makes it the leading illicit drug (17). Its prevalence has remained 
relatively stable worldwide over the past decade (17). The current prevalence in 
North America is estimated at 11% of the adult population (i.e., who report having 
consumed marijuana in the past year) (17). Although the prevalence has remained 
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relatively stable over the past decade, the concentration of THC in cannabis has 
increased from 4% to 13-17% percent since 1989 (38). In addition, a large number of 
new unregulated synthetic cannabinoids have been detected throughout the world, 
which are added to smoked cannabis (17). Little is known about the effects of these 
cannabinoids or about the extent of their use (17).  
Policies and legislation concerning cannabis use are wide-ranging across the 
world, from its use and possession being legal but age-limited such as in the 
Netherlands, to possession and use being illegal, such as in most states in the United 
States (58). In Canada, it is illegal to possess cannabis, although an exception is made 
for medical use of marijuana according to the Marijuana Medical Access Regulations 
(59). Despite this regulation, marijuana use is widespread among Canadians. In 
Canada, the prevalence of cannabis use in the past year declined from 14% of the 
adult population in 2004 to 9% in 2011 (60). Among students in grade 7 to 12 in 
Ontario, one in five reported past year use of marijuana in 2011, which was double 
the prevalence of past-year cigarette smoking (61).   
In Canada in 2011, a higher proportion of males consumed marijuana (12% 
compared to 7% of females) (60). The highest prevalence of use was  in British 
Columbia and Quebec, where rates substantially exceed the national average (62). In 
Quebec, 51% of students in grade 11 reported past-year use and the average age at 
initiation was 11 years old (38). Regular cannabis use defined as once a week or 
more, is reported by 8% of grade 11 students (38). In Quebec, one gram of cannabis 
is estimated to cost $10 (38).  
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2.3.2. Negative health effects 
There are numerous negative health effects related to cannabis use including 
decreased lung function, chronic obstructive disease, pneumothorax, respiratory 
infections, lung cancer, decreased cognitive function, mental health problems, 
impaired cardiovascular function as well as increased exposure to other substances of 
abuse such as alcohol and other illicit drugs (63-65). Aldington and Harwood (66) 
showed that the effect of one marijuana joint on lung cancer risk was approximately 
equivalent to the effect of 20 cigarettes. The effects of cannabis use on lung function 
have not received as much attention as its effects on mental health and cognitive 
functioning. There is an increased risk of developing schizophrenia particularly in 
early initiators and in individuals with a psychotic predisposition (28, 67, 68). 
Associations with decreases in memory, reflex time and IQ have also been observed, 
although further investigation is required (69, 70). Cannabis use is more likely among 
individuals with anxiety and depression, particularly in women, and cannabis use 
may in fact induce these conditions (28). Cannabis use also acutely impairs cognitive 
function, which may underpin its association with motor vehicle accidents (65, 70, 
71).  Other acute effects include an increased heart rate and increased blood pressure, 
which may lead to complications in individuals pre-disposed to developing 
cardiovascular disease (63, 65). Finally, as suggested by the Gateway and Reverse 
Gateway theories, other possible consequences of cannabis use include an increased 
risk of initiating other substances of abuse (20, 72). As the frequency of cannabis use 
increases, use of other illicit drugs and cigarettes also increase (72, 73).  
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2.3.3. Correlates of use 
Cannabis use relates to numerous factors including sex, age, childhood 
socioeconomic status (SES), sedentary behavior, physical activity, diet, alcohol use, 
smoking status and mental health (67, 74-78). The following section elaborates on 
each of these using data from Quebec or Canada when available.  
Cannabis use is more prevalent in males than females worldwide including in 
Canada and Quebec, and its use is most common in younger age groups (12, 17, 62). 
In Canada, the prevalence of past-year use increases until age 20 years and then 
decreases in each subsequent age category (62). In 2011, 22% of youth aged 15-24 
years had used cannabis in the past-year, which was three times the prevalence 
among adults aged 25 years or older (7%) (60). A systematic review of 11 studies 
concluded that there was a significant association between low childhood SES and 
subsequent cannabis use, a finding that was consistent across studies that specifically 
examined the predictors of cannabis use (77, 79).  
Increased sedentary behavior, and in particular computer and videogame 
screen time, and decreased physical activity are both associated with increased 
cannabis use in prospective studies (75, 78, 80). Cannabis users consume more 
sodium and calories than non-users and this relates primarily to increased fatty food 
consumption (23, 76, 81). Their alcohol intake is also higher than among non-users, 
which relates to increased beer and liquor consumption (23, 81). Cannabis use is 
more likely among individuals suffering from anxiety and depression (and, as 
indicated earlier, may in fact induce these states), possibly because individuals with 
these mental health conditions self-medicate with cannabis (67, 82, 83). Finally, 
cannabis users are more likely to smoke cigarettes than non-users (84). One study 
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conducted in the U.S. reported that 90% of cannabis users reported lifetime cigarette 
smoking (19).  
2.4.Cigarette smoking 
2.4.1. Tobacco exposure among cannabis users  
As mentioned previously, cannabis and cigarette smoking tend to co-occur 
since they are often used within the same social environment and they share a 
common method of delivery - inhalation (19, 72, 84-86). Cannabis users who do not 
smoke cigarettes may nevertheless be exposed to tobacco directly by “chasing”, 
which refers to smoking a cigarette immediately or shortly after smoking cannabis 
(86, 87). Even cannabis users who do not self-identify as cigarette smokers or smoke 
cigarettes may be exposed directly to tobacco through mulling or blunt smoking (86). 
Mulling refers to adding tobacco to cannabis prior to smoking (19, 88). It is a 
common practice in Europe where one study found that four of five cannabis smokers 
in Switzerland reported mulling. A second study conducted in the U.K. reported that 
89% of cannabis users reported mulling (88). No study has yet investigated mulling 
in North America.  
Blunt smoking is thought to be most common in North America (19, 89). A 
blunt consists of a cigar shell that is stuffed with cannabis (87-89). Smoking blunts 
exposes individuals to the tobacco and the tobacco toxins that remain in the shell. 
Although still under investigation, anecdotal reports suggest that individuals 
complement their cannabis smoking with tobacco in order to prolong the effects of 
cannabis, as well as increase alertness while under the euphoric effects of cannabis 
(90).  
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2.4.2. Contrasting and parallel effects of cannabis and cigarette use  
Two studies that reviewed the literature examining the joint effects of 
cigarette and cannabis use identified cigarette smoking as an important effect 
modifier of the effects of cannabis on the ECS (19, 20). Nicotine and THC have both 
contrasting and parallel effects on addiction processes and on appetite and body 
weight (19, 20). In animal studies, nicotine and THC enhance each other’s rewarding, 
physiological and behavioral effect (20). Correspondingly, regular administration of 
the CB1 antagonist, rimonabant, resulted in decreased nicotine self-administration 
(20). Finally, qualitative studies indicate that smoking one of the two substances 
reinforces the other and makes cessation more challenging due to their shared route 
of administration and social environments (85). 
Contrasting effects are apparent with respect to appetite. Nicotine increases 
metabolic rate and decreases appetite, whereas cannabis stimulates appetite (20). 
Both act in opposing ways on leptin and NPY (20). Nicotine and cannabis exhibit 
both parallel and contrasting effects with respect to withdrawal symptoms. Cannabis 
cessation is accompanied by anger, nervousness or anxiety, craving, difficulty 
sleeping, decreases in appetite, weight loss and depressed mood (19, 20). Nicotine 
withdrawal is characterized by very similar effects on mood and craving, but rather 
than weight loss, it is accompanied by weight gain (19, 20).  
2.5. Conceptual model 
Based on the findings in this literature review, a conceptual map was developed 
to depict the complexity of the possible associations between cannabis use, the ECS 
and adiposity, as well as with the many other factors identified as linked to cannabis 
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(Figure 2.1, p.21 and Figure 2.2, p.23). It places the associations of interest in public 
health, physiological and population-based contexts. Sex-specific differences in 
associations and the associations between cigarette smoking and its covariates were 
omitted, since their inclusion would have rendered the map too complex.  
Figure 2.1: Conceptual map of the literature part A: cannabis use and society 
 
Bidirectional arrows indicate a cross-sectional association, while unidirectional indicate an 
association over time. Lines without an arrowhead indicate a sub-topic 
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Figure 2.2: Conceptual map of the literature part B: cannabis use, the endocannabinoid system and the metabolic syndrome 
  
Bidirectional arrows indicate a cross sectional association, while unidirectional arrows indicate an association over time. 
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2.6.Cannabis and adiposity: epidemiological research 
2.6.1. Summary of studies to date 
 Only seven studies to date have examined the relationship between cannabis 
use and adiposity, and these studies vary substantially in methods of data collection 
and analysis. The methods and results of these studies are summarized in Table 2.1 
(p.27). Three of five cross-sectional studies, each of which controlled for age, sex and 
smoking status reported a negative association between cannabis use and body mass 
index (BMI) (22, 23, 25). A study using data from the Third National Health and 
Nutrition Examination Survey (NHANES III) also adjusted for education and caloric 
intake in their model, although the adjusted results were not reported (23). However, 
unadjusted means did not demonstrate a dose-response relationship between cannabis 
use and BMI, although the mean BMI in current non-users was 26.6 compared to 
24.7 in weekly to daily users. Another study examined data from the National 
Epidemiologic Survey on Alcohol and Related Conditions (NESARC) and the 
National Co-morbidity Survey–Replication (NCSR) separately and modeled the 
association between cannabis use and obesity (BMI ≥30 versus BMI <30) (25). Using 
logistic regression, they demonstrated that in each survey, the prevalence of obesity 
was lower in cannabis users than non-users (25% and 22% among cannabis non-
users, 17% and 14% among cannabis users). A third large-scale cross-sectional study 
examined cannabis use and BMI in 2,566 Australian participants aged 21 year on 
average (22). They observed a negative dose-response trend between the risk of 
overweight/obese and cannabis use, after adjusting for mother’s education and 
alcohol consumption in addition to age, sex and smoking status. However, when 
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sensitivity analyses were conducted separately in men and women, more frequent 
cannabis use was associated with greater risk of overweight and obesity in both 
sexes. Finally, in  a sample of 297 overweight and obese women who had been 
referred to a weight management clinic (mean BMI = 46kg/m
2
), a negative 
association was detected between cannabis use and BMI category (r
2
 = 0.96, p = 
0.017) (21). This study, however, reported few details on the methods of data 
collection and analysis. One of the five cross-sectional studies which included 7,825 
students aged 11 to 17 years, reported that younger obese girls had a relative risk of 
frequent cannabis use that was three times that of normal weight girls (4). No 
association between cannabis consumption and weight in boys was observed. 
In the longitudinal Coronary Artery Risk Development in Young Adults 
(CARDIA) study, there was no independent association between cannabis use and 
measured BMI or WC and self-report cannabis use, after controlling for gender, race, 
age, alcohol use, daily physical activity, physical fitness, education, income levels 
and cigarette smoking (81). Finally in a randomized control trial conducted in 1976 
under ward condition (i.e., male participants were restricted to a hospital area), heavy 
cannabis users gained an average of 3.7 pounds (lbs), casual users gained 2.8 lbs and 
controls gained 0.2 lbs over a 21-day period of unlimited voluntary exposure (24). 
Given the date of the study and the lack of replication, its results should be 
interpreted with caution. 
2.6.2. Limitations of previous studies  
Cross-sectional studies that examine the association between cannabis use and 
adiposity cannot, by definition, model change in adiposity and therefore, the effect of 
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cannabis use on change in adiposity cannot be determined. These studies do suggest 
that cannabis users are not overweight or obese. Only two of the seven studies 
considered sex differences. None of these studies considered possible effect 
modification of the association by cigarette smoking.  
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Table I: Summary of studies that examine the association between cannabis use and adiposity 
Study Title / 
Reference  
Study Design 
Sample and 
Population 
Exposure 
measure 
Outcome 
measure 
Controls 
Method of 
analysis 
Results Conclusion Comments 
Effects of 
Marihuana Use on 
Body Weight and 
Caloric Intake in 
Humans. 
 
Greenberg, 
Kuehnle (24) 1976 
 Experimental 
controlled 
clinical trial  
 Male 
volunteers  
 12 casual 
cannabis 
users, 15 
heavy users 
and 10 
controls  
 2 groups of 
cannabis 
use and one 
control 
 Measured 
weight  
 Caloric 
intake 
 Groups were 
matched on 
socioeconomic 
status, level of 
education and 
intelligence 
 Comparison 
of means (t-
test)  
 Heavy and 
casual users 
gained an 
average of 3.7 
and 2.8 lbs 
respectively, 
while controls 
gained 0.2lbs 
 Marijuana 
use is 
associated 
with 
increasing 
weight gain 
 Ward 
conditions: 
four-bed 
clinical research 
ward of the 
Alcohol and 
Drug Abuse 
Research 
Center at the 
McLean 
Hospital  
 21 day period 
Dietary intake and 
nutritional status of 
US adult marijuana 
users: results from 
the Third National 
Health and 
Nutrition 
Examination 
Survey 
 
Smit and Crespo 
(23) 2001 
 Cross-sectional   Adults aged 
20-60 years 
who 
participated 
in NHANES 
III, 1988-
1994  
 n=10,623 
 Past-month 
marijuana 
use  
 Three 
categories 
 Body mass 
index 
 Dietary 
intake data 
 Age, gender, 
education, 
cigarette 
smoking and 
caloric intake 
 Comparison 
of means (t-
test) 
 BMI was 
lower in heavy 
users than 
non-users 
(p=0.003) 
 Total caloric 
intake was 
highest among 
heavy users 
 
 BMI was 
slightly 
lower and 
dietary intake 
was different 
in marijuana 
users 
compared to 
non-users 
 
 Caloric intake 
could be on the 
causal pathway 
and should not 
be controlled 
for 
 Nationally 
representative 
 
Body Mass Index 
and Marijuana Use 
 
Warren, Frost-
Pineda (21) 2005 
 Cross-sectional   Women from 
a weight 
management 
clinic 
  n=297 
 Past-year 
marijuana 
use 
 Measured 
BMI  
 Four 
categories  
 N/A  Linear 
regression 
 
 Negative 
correlation 
between BMI 
group and 
percent 
marijuana use 
 R2 = 0.96  
(p = 0.017) 
 As BMI 
increases, 
lower rates 
of marijuana 
use are found 
in females. 
 Missing 
information 
 Suggested 
mechanism for 
this association: 
competing 
effects on 
neurobiological 
reward sites 
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Marijuana Use, 
Diet, Body Mass 
Index, and 
Cardiovascular 
Risk Factors (from 
the CARDIA 
Study) 
 
Rodondi, Pletcher 
(81) 2006 
 Longitudinal 
study  (1985-
2000) 
 Participants 
in the 
CARDIA 
study  
 n=3,617 
 Past-month 
marijuana 
use 
measured 6 
times over 
15 years  
 Measured 
BMI and 
waist 
circumferen
ce 
 Dietary 
intake data 
 Race, gender, 
study centre, 
tobacco use, 
amount of 
alcohol per day, 
baseline level 
of the 
dependent 
variables 
 
 Multiple 
linear 
regression 
 Marijuana use 
was associated 
with higher 
caloric intake 
and alcohol 
use 
  Marijuana use 
was not 
significantly 
associated 
with BMI or 
waist 
circumference 
 Marijuana 
use was not 
associated 
with BMI, 
but was 
associated 
with alcohol 
use, tobacco 
use, and high 
caloric 
intake. 
 The relationship 
between BMI 
and marijuana 
use was 
confounded by 
alcohol use 
Cannabis Use and 
Obesity and Young 
Adults 
 
Hayatbakhsh, 
O'Callaghan (22) 
2010 
 Cross-sectional  
 
 Participants  
(age 21) of 
MUSP Study 
 n=2,566 
 
 Past-month 
marijuana 
use and age 
of onset 
 Four 
categories 
 Measured 
BMI 
 Two 
categories: 
BMI<25 
and 
BMI≥25 
 Mother’s age 
and level of 
education, age, 
sex, cigarette 
smoking, 
alcohol 
consumption, 
mental health, 
BMI at 14. 
 Multivariate 
logistic 
regression  
 Cannabis 
users were 
less likely to 
be categorized 
in the BMI ≥ 
25 group 
 Least 
prevalence 
observed in 
daily users 
(OR=0.2) 
 Cannabis 
users were 
less likely to 
be 
overweight. 
 Sensitivity 
analysis 
indicated an 
inverse 
association 
observed when 
males and 
females 
examined 
separately 
Overweight, 
Obesity, Youth, 
and Health-Risk 
Behaviors.  
 
Farhat, Iannotti (4) 
2010 
 Cross-sectional   Participants 
(age 11-17) 
of the  
Health 
Behaviors in 
School-Aged 
Children 
survey 
 n=7,825 
 Life-time 
cannabis use 
 Three 
categories: 
abstainer, 
used once or 
twice, or 
other 
 Self-report 
BMI  
 Two 
categories:  
BMI<25 
and 
BMI≥25 
 SES, race and 
family 
composition  
 Multinomial 
and logistic 
regression 
models 
 Stratifıed by 
gender and 
age  
 Obesity was 
associated 
with cannabis 
use among 
younger girls 
only (OR 3.4) 
 
 There is a 
higher 
likelihood of 
substance 
use, among 
overweight 
and obese 
girls.  
 Positive non-
significant 
association 
between 
cannabis use 
and BMI. 
 9% of sample 
reported a 
lifetime 
cannabis use    
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Obesity and 
Cannabis Use: 
Results From Two 
Representative 
National Surveys 
 
Le Strat and Le 
Foll (25) 
2011 
 Cross-sectional  Participants 
(age ≥18) of 
the 
NESARC 
and NCS-R 
 n=9,879 & 
n= 2,283 
 Past-year 
cannabis 
use 
 Four 
categories 
 Self-report 
BMI 
 Two 
categories: 
BMI<30 
and 
BMI≥30   
 Sex, age, 
race/ethnicity, 
educational 
level, marital 
status, region of 
residence and 
smoking status 
 Linear and 
logistic 
regression  
 The 
prevalence of 
obesity was 
lower in 
cannabis users 
than non-users 
(16% vs. 22% 
and 17% vs. 
25%)  
 Cannabis 
users are less 
likely to be 
obese than 
non users. 
 Low 
prevalence of 
cannabis users 
(4% and 7% 
report past-
year use)  
 
 
 Chapter 3: Objective and hypotheses 
This thesis uses data from the Nicotine Dependence in Teens (NDIT) Study (a 
prospective (1999-2013) cohort investigation of the natural course of nicotine 
dependence that collected data from 1,293 students aged 12-13 years from ten 
secondary schools in Montreal) to examine the possible link between cannabis use 
and change in adiposity in young adults. The specific objectives were to describe, in 
males and females separately, the association between cannabis use and change in 
adiposity over time, and to test if the association is modified by cigarette smoking. 
Based on the pharmacological and neurobiological evidence in the literature, it is 
hypothesized that:    
i) Cannabis use is associated with greater increases in adiposity over time.  
ii) The association between cannabis use and change in adiposity is modified 
by cigarette smoking such that cigarette smoking attenuates the 
association.  
 Chapter 4: Methods 
4.1. Data source 
Data for this current analysis were drawn from the  Nicotine Dependence in 
Teens (NDIT) Study, an ongoing prospective cohort investigation of the natural 
course of nicotine dependence in 1,293 students aged 12-13 years at cohort inception. 
Participants were recruited from all grade seven classes in a convenience sample of 
ten secondary schools located in or near Montreal, Canada, and selected to include a 
mix of French and English schools, schools located in urban, suburban, and rural 
areas, and schools in advantaged and disadvantaged neighbourhoods. Thirteen 
schools were selected initially. One school was excluded because school 
administrators could not guarantee continued participation in the study over at least 
five years, and two additional schools were excluded due to low response 
proportions. Approximately half (55%) of eligible students participated - the low 
response proportion related to students’ or parents’ reluctance for their child to 
participate in the blood draw for genetic analysis, and to an ongoing labour dispute in 
which teachers refused to collect consent forms. 
During the five years of secondary school, from grade 7 to 11 (1999 – 2005), 
data were collected from students in self-report questionnaires administered at school 
every three months during the 10-month school year, for a total of 20 survey cycles. 
Post-secondary school data were collected in mailed self-report questionnaires when 
participants were age 20 and 24 years on average, in survey cycles 21 and 22, 
respectively. The self-report questionnaires collected extensive data on cigarette 
smoking, as well as on other risk factors for chronic disease including physical 
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inactivity, sedentary behaviors, poor diet, alcohol use, and psychosocial 
characteristics. Data on illicit drug use and mental health were collected in survey 
cycles 21 and 22. Anthropometric characteristics (height, weight, waist 
circumference (WC), skinfold thickness) and blood pressure were measured in survey 
cycles 1, 12, 19 and 22, and blood and saliva samples were collected in grade 9 and 
in survey cycles 21 and 22 to enable investigation of genetic risk factors. Finally, 
parental data were collected in 2007.  
The NDIT Study is funded by the Canadian Cancer Society. At baseline, 
participants provided assent and a parent or guardian provided written informed 
consent. Participants themselves provided informed consent in the post-secondary 
school data collections. NDIT received ethics approval from the Montreal 
Department of Public Health Ethics Review Committee, the McGill University 
Faculty of Medicine Institutional Review Board and the Ethics Review Committee at 
the CRCHUM. 
4.2. Study Design 
The objectives of this thesis were addressed in a prospective cohort study design 
stratified by sex, which examined the associations between past year cannabis use 
(measured in survey cycle 21 when participants were age 20.4 years on average) and 
change in BMI and WC over seven years during young adulthood (i.e., from survey 
cycle 19 to 22). Although BMI and WC are both indicators of adiposity, contrasting 
results across these two outcomes could indicate a difference in lipodistophy (i.e., the 
functioning of different types of adipose tissue). This speculation is supported by the 
physiological importance of the ECS in adipose tissue regulation. Covariates 
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included physical activity, sedentary behavior and alcohol use (in males only) which 
were measured in survey cycles 17-20, when participants were in grade 11 and age 
17 years on average. BMI and WC as measured in survey cycle 19 were also 
included as covariates. 
4.3. Analytic sample   
Eligibility criteria for inclusion in the current analysis were that the: 
(i) participant completed the self-report questionnaire in survey cycle 21, which 
collected data on lifetime as well as current frequency of cannabis use and self-
reported height and weight. A total of 880 of 1,293 NDIT participants completed 
survey cycle 21, of which 404 were male and 476 were female.  
(ii) participant had values for measured height and weight in survey cycle 22. Of 
880 participants who completed self-report questionnaires in survey cycle 21, 160 
were excluded based on this criterion. Therefore the analytic samples were reduced to 
327 males and 393 females.  
(iii) participant had values for measured height and weight in survey cycle 19 or 
self-reported height and weight in survey cycle 21. No participants were excluded 
based on this criterion.  
(iv) participant had values for measured WC in survey cycle 19. For analyses 
conducted using change in WC as the outcome variable, 180 participants were 
excluded based on this criterion, so that the analytic subset was reduced to 256 males 
and 284 females. 
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(v) participant had complete data on the exposure, outcome and covariates. A 
further 130 participants were excluded due to missing data, erroneous measures, or 
outliers. Therefore the final analytic samples for the analysis conducted using BMI 
were 271 males and 319 females. Analyses conducted using change in WC as the 
outcome variable included 250 males and 283 females.  
4.4. Study variables 
The specific questionnaire items that are relevant to this thesis are described in 
Appendix 1. 
4.4.1. Cannabis use 
Cannabis use was measured in survey cycle 21 by: “In the past 12 months 
how often did you… use marijuana, cannabis, hashish”. Response choices included: 
“never”, “less than once per month”, “1-3 times per month”, “1-6 times per week”, or 
“every day, which were re-coded for analysis to represent weekly frequency of use 
(i.e., 0, 0.1, 0.4 3, and 7 times per week). 
4.4.2. Cigarette smoking 
Lifetime cigarette use was measured in all survey cycles by: “Have you ever 
in your life smoked a cigarette, even just a puff (drag, hit, haul)?” Participants who 
responded no were coded as smoking 0 cigarettes per day. Participants who 
responded “yes” completed a 3-month recall of cigarette use which included the three 
questions presented in Table II (p.39). Questions 1 and 2 were asked for each of the 
three months preceding questionnaire administration.  
For analysis, mean number of cigarettes smoked per day in each of the past 
three months was computed as the number of days smoked per month multiplied by 
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the number of cigarettes usually smoked each day on the days that the participant 
smoked. The mean number of cigarettes smoked per day was averaged across the 
three months. Test-retest reliability of the past three-month recall is very good (91). 
A total of 232 participants were missing data on past three-month cigarette smoking; 
cigarette smoking for these participants was imputed based on their response to 
question 3 in Table II (p.39). 
Table II: Questionnaire items, response choices and coding used to represent daily cigarette 
smoking 
Questionnaire item Response choices Coding used 
1. “How many days did you smoke 
cigarettes, even just a puff during 
[the last month, month before last, 
and the before last month]?” 
None 0 days 
1 day 1 day 
2-3 days 2.5 days 
4-5 days 4.5 days 
6-10 days 8 days 
11-15 days 13 days 
16-20 days 18 days 
21-30 days 25.5 days 
Every day 30 days 
Don’t know Missing 
2. “On the days that you smoked 
during [the last month, month 
before last, and the before last 
month], how many cigarettes did 
you usually smoke each day?” 
< 1 cigarette 0.5 cigarettes 
2-3 cigarettes 2.5 cigarettes 
4-5 cigarettes 4.5 cigarettes 
6-10 cigarettes 8 cigarettes 
11-15 cigarettes 13 cigarettes 
16-20 cigarettes 18 cigarettes 
21-25 cigarettes 23 cigarettes 
>25 cigarettes 26 cigarettes 
3. “Check the box that describes 
you best…”. 
“I have smoked cigarettes, but 
not at all in the past 12 months” 
0 cigarettes/day 
“I smoked cigarettes once or a 
couple of times in the past 12 
months” 
0.01 cigarettes/day 
“I smoke cigarettes once or a 
couple of times each month” 
0.05 cigarettes/day 
“I smoke cigarettes once or a 
couple of times each week” 
0.2 cigarettes/day 
“I smoke cigarettes every day” 1 cigarettes/day 
4.4.3. Anthropometric measures 
Height, weight and WC were measured in survey cycles 19 and 22 by trained 
technicians according to standardized protocols (92). Two measures to the nearest 
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0.1cm for height and WC, and 0.2kg, for weight, were recorded. If they differed by 
more than 0.5cm and 0.2kg respectively, a third measure was taken, and the  average 
of the two closest measures was used in the analysis. Inter-rater reliabilities (split-half 
coefficients) computed using repeat measures for one in 10 participants were 0.99, 
0.99, and 0.98  for height, weight and WC, respectively (93). Body mass index (BMI) 
was computed by dividing weight (in kg) by height (m
2
). Change in BMI and WC 
over time was computed for each participant by subtracting their BMI or WC value 
from survey cycle 19 from the BMI or WC values in survey cycle 22.  
Because 189 participants were missing anthropometric data in survey cycle 
19, we modeled BMI for survey cycle 19 using data on self-report height and weight 
(i.e., BMI) from survey cycle 21 according to the following linear regression:  
                            
Values predicted using this equation were strongly correlated with measured BMI in 
survey cycle 19 (r= 0.83; p<0.001) among participants with measured height and 
weight in survey cycle 19. Because there were no data on self-report WC in survey 
cycle 21, imputation of WC values for survey cycle 19 was not possible.  
4.4.4. Covariates 
Socio-demographic characteristics  
Data on sex, which were collected in multiple surveys, were verified for 
consistency across survey cycles. Data on mother’s education were collected in the 
parental questionnaire and coded for analysis as mother university-educated (yes, 
no). 
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Physical activity  
Physical activity was assessed in a 7-day recall in which participants  
recorded on which day(s) during the previous week they had participated in any of 29 
common physical activities for ≥ 5 minutes (94). Activities were categorized as light, 
moderate, or vigorous, and the number of times the participants reported moderate or 
vigorous activities per week summed and averaged over survey cycles 17-20 (95). 
The moderate/vigorous physical activity score ranged from 0 to 55 times per week. 
Sedentary behavior  
Computer time was measured by asking participants to indicate the number of 
hours spent per day using the internet, working on the computer or playing 
videogames. In addition, participants were asked to indicate, the number of hours 
spent watching television on weekdays and on weekends. Number of hours per day 
on weekdays was multiplied by five and added to number of hours per day on 
weekends multiplied by two. This sum was then divided by seven to provide an 
average number of hours of television per day. Values >18 hours per day was deemed 
not possible and coded as missing.  
Alcohol use 
Alcohol use was measured in survey cycle 17-20 by asking participants how 
often they drank alcohol in the past month. Response choices included never, a bit to 
try, once or a couple of times a month, once or a couple of times a week, daily, which 
were re-coded as 0, 0.5, 2, 8, and 30 times per month. Responses across survey cycles 
were averaged to represent mean monthly alcohol consumption.   
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Mental health  
Mental health was assessed using three indicators. In survey cycles 17 to 20, a 
score was computed for each participant based on the 6-item Mellinger depression 
symptoms scale (96, 97). Participants were asked how often in the past three months 
they had felt: too tired to do things; felt hopeless about the future; felt nervous or 
tense; worried too much about things; had trouble going to sleep or staying asleep; 
felt unhappy, sad or depressed. Response choices included never, rarely, sometimes, 
and often scored 1, 2, 3, and 4,  respectively. An average of the scores was computed, 
resulting in values that ranged from 1 to 4. Participants who responded to fewer than 
four of the six items were coded as missing. Scores across survey cycles 17-20 were 
averaged. Participants with higher scores had more depressive symptoms. In addition 
to the depression score, in survey cycle 21, participants were asked if a health 
professional had ever diagnosed them (yes, no) with a mood disorder (i.e., 
depression, bipolar disorder) or an anxiety disorder (i.e., phobia, fear of social 
situations, obsessive-compulsive disorder, panic disorder, generalized anxiety 
disorder).   
4.5. Data analysis 
4.5.1. Descriptive analysis  
The frequency distributions of the outcome variables were examined to 
ensure they was normally distributed and to identify outliers. Their distributions were 
also examined according to each categorical variable. Frequency distribution of 
continuous variable and their mean, range and variance were used to detect 
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implausible values and possible outliers. Implausible values were re-coded as 
missing.  
The number of participants with missing data for each variable is described in 
Table III (p.43). The final BMI regression models, which included only participants 
with complete data, included of 271 males and 319 females. The final WC regression 
models included 250 males and 283 females. 
The sample was stratified by sex and described according to socio-
demographic and lifestyle characteristics. Cannabis use, change in BMI and change 
in WC were examined according to socio-demographic and lifestyle characteristics in 
each group. An ANOVA was used to test for differences between means for the 
continuous variables grouped by each categorical variable.  
4.5.2. Univariate analyses   
Mean change in BMI and WC over seven years (from survey cycle 19 to 22) 
for each sex was plotted by frequency of cannabis use. In order to accommodate the 
U-shaped association indicated in the figures, a quadratic term was created by 
computing the square of the cannabis variable. The crude association was further 
examined in polynomial regression models of change in BMI or WC predicted by 
Table III: Number of participants with missing data according to study variable 
Variable Missing from analytic 
sample for BMI analyses 
n 
Missing from analytic 
sample for WC analyses 
n 
Male Female Male Female 
Maternal education 27 34 9 7 
Sedentary behavior 51 72 0 0 
Alcohol use 52 72 0 0 
Physical activity 53 73 2 1 
Depression symptoms 51 72 0 0 
Diagnosed anxiety or mood disorder 2 0 2 0 
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cannabis use and cannabis use squared. This method was selected to take advantage 
of the continuous nature of the outcome variables, and to accommodate the U-shaped 
association observed in the univariate analysis. 
4.5.3. Multivariate analyses  
Potential confounders of the association between cannabis use and change in 
adiposity were selected based on a correlation matrix as those variables that were 
correlated at r ≥0.2 with cannabis use. Among male participants, alcohol use was the 
only variable correlated with cannabis use at this level. In female participants, none 
of the covariates examined were correlated with cannabis use at this level. Although 
not correlated at r ≥0.2, physical activity and sedentary behavior were included in the 
models, since these variables are widely believed to be associated with adiposity. 
Finally, baseline BMI and baseline WC were included in the models to account for 
biological and/or societal predisposition for a high BMI or WC.  
The association between cannabis use and change in each of the two adiposity 
indicators (BMI and WC) was examined multivariately in polynomial regression 
models for each sex separately. The adjustment for alcohol use was only included in 
the model fitted to the male participants’ data, and is not presented in the equations 
below. The first model for female participants (which does not include an interaction 
term between cannabis use and cigarette smoking) is represented by the following 
two equations (one equation for each outcome variable): 
i.       
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ii.      
                          
 
                                            
                                     
The second model fitted to female participants’ data included interaction terms to 
test if the association between cannabis use and change in adiposity indicators was 
modified by cigarette smoking:  
i.                                 
 
                                  
                                     
 
                   
                                                               
ii.                                
 
                                  
                                     
 
                   
                                                           
The statistical significance of each beta coefficient was determined using the 
Wald test. To test the combined significance of the pair of interaction terms for both 
the BMI and WC models, a full model, which included the interaction terms 
“cannabis use and cigarette smoking”, and “cannabis use squared and cigarettes 
smoking”, was compared to a reduced model, which excluded the two interaction 
terms using a likelihood ratio test. This test follows a χ2 distribution with 2 degrees of 
freedom (the difference in the degrees of freedom of the full and reduced models).  
After fitting the initial models, possible multicollinearity related to inclusion of 
collinear terms (i.e., cannabis use, cannabis use squared, their interaction terms) was 
investigated by examining the variance inflation factors (VIFs). Multicollinearity was 
an issue as evidenced by VIFs that exceeded 10 for cannabis use, cannabis use 
squared, cigarette smoking and the interaction terms. To rectify this situation, 
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cannabis use and cigarette smoking were each centered around a constant (i.e., the 
mean corresponding to a value of 2.257 times per week for cannabis use, and 4.940 
cigarettes per day for cigarette smoking) in both sexes. These values were subtracted 
from each cannabis use and cigarette smoking value. The VIFs for the models that 
incorporated centered values for cannabis use and cigarette smoking were reduced to 
values deemed tolerable. 
The residuals of each model were examined to ensure that model assumptions 
were met, to identify outlying residuals and to assess the stability of the model. This 
was completed by viewing the distribution of the standardized residuals to ensure that 
they were normally distributed. A normal probability plot of the standardized 
residuals was also examined to assess the distribution of the residuals. Scatter plots 
were used to ensure that the error was equally distributed across independent 
variables, and that no patterns were observed. Outlying values were identified by 
examining the magnitude of the standardized residuals. Potentially outlying values 
were re-examined and their influence on the model assessed. Influential values were 
examined using Cook’s Distance and Leverage values. The influence of large values 
on the beta coefficients was analyzed. These values served as an indication of the 
stability of the model. 
Because interpretation of a polynomial regression with an interaction term 
and centered variables is challenging, we plotted the association between cannabis 
use and change in BMI and WC in each final model for two hypothetical individuals 
– one who smoked half a cigarette per day, and one who smoked 15 cigarettes per 
day. Finally, a three dimensional graphing tool was used to identify the approximate 
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stationary points of the curve in models containing an interaction term and 
rearrangement of the model equations used to determine their values. All statistical 
analyses were conducted using the IBM SPSS Statistics package version 20 
(International Business Machines Corp., Armonk, NY). 
 Chapter 5: Manuscript 
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contributions to this work were the development of the initial idea for this study, the 
completion of the literature review, the statistical analysis, interpretation of the 
findings and the writing of the thesis and manuscript. The support, guidance and 
critiques of my supervisors: Dr. J. O’Loughlin, Dr. D. Jutras-Aswad and Dr. I. Karp 
were essential in each step in this study and to my development as a researcher. The 
figures and tables that could not be incorporated into the manuscript due to space 
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Abstract 
Aim: To test the hypothesis that the association between cannabis use and change in 
adiposity is modified by cigarette smoking.  
Design: Cohort study  
Setting: Montreal, Canada 
Participants: 271 males and 319 females aged 24 years on average participating in 
the Nicotine Dependence In Teens (NDIT) Study, a 13-year prospective cohort 
investigation of the natural course of nicotine dependence. 
Measurements: Cannabis use was measured as past-year cannabis use when 
participants were 20 years of age on average. Cigarette smoking was also measured 
at age 20 years as the number of cigarettes per day over a three-month recall period. 
Outcome measures included change in body mass index (BMI) and in waist 
circumference (WC) from age 17 to 24 years.  
Data analysis: Possible effect modification of the associations between cannabis use 
and change in BMI and change in WC by cigarette smoking was tested in polynomial 
linear regression models adjusting for covariates in males and females separately.  
Findings: In males, the interaction between cannabis use and cigarette smoking was 
statistically significant in both the model for change in BMI (p=0.004) and the model 
for change in WC (p=0.036). In females, the interaction between cannabis use and 
cigarette smoking was not statistically significant in either model. Cannabis use was 
associated with change in adiposity in a U-shaped association in females and in male 
non-smokers, and in an inverted U-shaped association in male smokers. 
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Conclusion:  Smoking cigarettes appears to attenuate the association between 
cannabis use and change in adiposity in young men, but not in young women.  
Introduction 
The ongoing obesity epidemic is of considerable concern worldwide. In 
Canada, 62% of the population is overweight or obese, and the healthcare burden 
associated with obesity is estimated at $4.3 billion annually in direct and indirect 
costs (1, 2). Extensive research has identified numerous risk factors for excess body 
weight including poor diet and low levels of physical activity, which have both been 
important targets for lifestyle-oriented public health programs and policy. A target of 
pharmaceutical weight loss interventions has been the endocannabinoid system 
(ECS), since its over-activation is associated with overweight and obesity (8, 9, 31). 
The ECS is implicated in the maintenance of energy homeostasis through its 
signalling molecule and receptors, which include the cannabinoid-1 (CB1) and 
cannabinoid-2 (CB2) receptors (14). ECS receptors in the central nervous system are 
involved in motivation to eat, perceived palatability of food, suppression of aversive 
memory, creation of a stress response and emotional regulation (9, 28, 29). Through 
its peripheral receptors, the ECS is implicated in virtually every aspect of the 
metabolic syndrome and its associated symptoms including insulin sensitivity, 
glucose uptake, fat deposition, appetite hormone regulation, hypertension, 
cardiovascular disease, atherosclerosis, systemic inflammation, and permeability of 
the gut (13, 14, 30). 
ECS actions differ according to sex at a cellular level and at the endocrine 
level due to an interaction with the sex hormones (10-12). Its homeostatic effects as a 
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result of stimulation by exogenous cannabinoids are more extreme in men, while its 
effects on mood, particularly anxiety and depression, are more extreme in women 
(10). 
Cannabis is the most widely used illicit drug in the world, with an estimated 125 
to 203 million users in 2009 (17). Its use relates to age, childhood socioeconomic 
status (SES), sedentary behavior, physical activity, diet, alcohol use, smoking status 
and mental health, and its use is more common in men than women (67, 74-78). The 
non-synthetic cannabinoid that first led to the identification of the CB1 receptor, was 
delta-9-tetrahydrocannabinol (THC), the active component of the cannabis sativa 
plant, which acts agonistically on the receptor (18).  
The immediate effects of THC on appetite are well-known and synthetic 
derivatives of THC are used for their orexigenic effects in patients suffering from 
anorexia nervosa and acquired immune deficiency syndrome (14, 16). However, 
there are numerous negative health consequences that can result from smoking 
cannabis including impaired lung function (i.e., chronic obstructive disease, 
pneumothorax, respiratory infections, and lung cancer), cognitive function, mental 
health, cardiovascular function as well as increased exposure to other substances of 
abuse such as alcohol and illicit drugs  (63-65).  
When used recreationally, cannabis is smoked and often co-used or used 
simultaneously with tobacco (19). Among cannabis users in the U.S., 90% reported 
having been a cigarette smoker (19). Cannabis users who do not self-identify as 
cigarette smokers or smoke cigarettes may also be exposed directly to tobacco 
through mulling (86), which refers to adding tobacco to cannabis prior to smoking, 
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and is a common practice in Europe (19, 88). No study has yet investigated mulling 
in North America.  
Human and animal studies examining the joint effects of cigarette and 
cannabis use have identified nicotine as an important modifier of the action of THC 
on the ECS (20). Nicotine and THC have both contrasting and parallel effects on 
addiction processes and on appetite and body weight (19, 20). Nicotine increases 
metabolic rate and decreases appetite, while cannabis stimulates appetite (20). Both 
act in opposing ways on leptin and neuropeptide Y (NPY), two hormones involved in 
digestion (20). These differences become evident in cessation: cannabis cessation is 
accompanied by a decrease in appetite and weight loss, while nicotine withdrawal is 
accompanied by increased weight and cravings (19, 20).  
To date, studies that investigate the association between cannabis use and weight 
are inconclusive (4, 21-25). Most extant studies are cross-sectional and none have 
specifically tested for modification of the effect of cannabis use on change in 
adiposity by cigarette smoking. Also, few studies have investigated possible 
differences in these associations according to sex. This current study describes the 
association between cannabis use and change in adiposity in males and females 
separately, and tests if this association is modified by cigarette smoking. We 
hypothesize, given that THC stimulates the ECS and over-activation of the ECS is 
observed in overweight and obese individuals, that cannabis use leads to weight gain, 
but that this effect is modified by cigarette smoking. 
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Methods  
Data were drawn from the Nicotine Dependence in Teens (NDIT) Study, an 
ongoing prospective cohort investigation of the natural course of nicotine dependence 
in 1,293 students aged 12-13 years at cohort inception. Participants were recruited 
from all grade seven classes in a convenience sample of ten secondary schools 
located in or near Montreal, Canada, which were selected to include a mix of French 
and English schools, schools located in urban, suburban, and rural areas, and schools 
in advantaged and disadvantaged neighbourhoods. Thirteen schools were selected 
initially. One school was excluded because school administrators could not guarantee 
continued participation in the study over at least five years, and two additional 
schools were excluded due to low response proportions. Approximately half (55%) of 
eligible students participated - the low response proportion related to students’ or 
parents’ reluctance for their child to participate in the blood draw for genetic 
analysis, and to an ongoing labour dispute in which teachers refused to collect 
consent forms. 
During the five years of secondary school, from grade 7 to 11 (1999 – 2005), 
data were collected from students in self-report questionnaires administered at school 
every three months during the 10-month school year, for a total of 20 survey cycles. 
Post-secondary school data were collected in mailed self-report questionnaires when 
participants were age 20 and 24 years on average, in survey cycles 21 and 22, 
respectively. The self-report questionnaires collected data on cigarette smoking, as 
well as on physical activity, sedentary behaviors, diet, alcohol use, and psychosocial 
characteristics. Data on illicit drug use were collected in survey cycles 21 and 22. 
Anthropometric characteristics (height, weight, waist circumference (WC)) were 
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measured in survey cycles 1, 12, 19 and 22. Finally parental data, including maternal 
education, were collected in 2007. 
Study variables  
Cannabis use frequency was measured by: “In the past 12 months how often 
did you… use marijuana, cannabis, hashish”. Response choices included: “never”, 
“less than once per month”, “1-3 times per month”, “1-6 times per week”, or “every 
day”, which were re-coded for analysis to represent weekly frequency of use (i.e., 0, 
0.1, 0.4, 3, and 7 times per week, respectively). 
Lifetime cigarette use was measured by: “Have you ever in your life smoked 
a cigarette, even just a puff (drag, hit, haul)?” Participants who responded no were 
coded as smoking 0 cigarettes per day. Participants who responded “yes” completed a 
3-month recall of cigarette use which included two items: (i) “On how many days did 
you smoke cigarettes, even just a puff during [the last month, month before last, and 
two months before last]?” for each of the past three months; and (ii) “On the days 
that you smoked during [the last month, month before last, and the before last 
month], how many cigarettes did you usually smoke each day?” Mean number of 
cigarettes smoked per day in each of the past three months was computed as the 
number of days smoked per month multiplied by the number of cigarettes usually 
smoked each day on the days that the participant smoked divided by 30. The mean 
number of cigarettes smoked per day was averaged across the three months. Test-
retest reliability of the past three-month recall is very good (91).  
Height, weight and WC were measured by trained technicians according to 
standardized protocols (92). Two measures to the nearest 0.1cm for height and WC, 
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and 0.2kg, for weight, were recorded. If they differed by more than 0.5cm or 0.2kg 
respectively, a third measure was taken, and the average of the two closest measures 
was used in the analysis. Inter-rater reliabilities (split-half coefficients) computed 
using repeat measures for one in 10 participants were 0.99, 0.99, and 0.98  for height, 
weight and WC, respectively (93). Body mass index (BMI) was computed by 
dividing weight (kg) by height (m
2
). Change in BMI and WC between age 17 and 24 
years were computed by subtracting the value of BMI and WC in survey cycle 19 
from their values in survey cycle 22.  
A total of 189 participants were missing anthropometric data in survey cycle 
19. In order to impute these missing data, a regression model was fitted using data for 
participants who had both anthropometric measurements in survey cycle 19 and self-
report data in survey cycle 21. The regression model was used to impute BMI in 
survey cycle 19 as a function of self-report BMI in survey cycle 21. Values thus 
predicted were strongly correlated with actual measured BMI values in survey cycle 
19 (r=0.83; p<0.001).  
Data on mother’s education were collected in the parental questionnaire and 
coded for analysis as mother university-educated (yes, no). 
Physical activity was assessed in a 7-day recall in which participants recorded 
on which day(s) during the previous week they had participated in any of 29 common 
physical activities for ≥5 minutes (94). Activities were categorized as light, moderate, 
or vigorous, and the number of times the participants reported moderate or vigorous 
activities per week was summed and averaged over survey cycles 17-20 (95). The 
moderate/vigorous physical activity score ranged from 0 to 55 times per week. 
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Sedentary behavior was measured by first asking participants to indicate the 
number of hours spent per day using the internet, working on the computer or playing 
videogames. In addition, participants were asked to indicate, the number of hours 
spent watching television on weekdays and on weekends. Number of hours per day 
on weekdays was multiplied by five and added to number of hours per day on 
weekends multiplied by two. This sum was then divided by seven to provide an 
average number of hours of television per day. Values >18 hours per day was deemed 
not possible and coded as missing. 
Alcohol use was measured in survey cycle 17-20 by asking participants how 
often they drank alcohol in the past month. Response choices included never, a bit to 
try, once or a couple of times a month, once or a couple of times a week, daily, which 
were re-coded as 0, 0.5, 2, 8, and 30 times per month. Responses across survey cycles 
were averaged to represent mean monthly alcohol consumption.   
Mental health was assessed using three indicators. In survey cycles 17 to 20, a 
score was computed for each participant based on the 6-item Mellinger depression 
symptoms scale (96, 97). Participants were asked how often in the past three months 
they had felt: too tired to do things; felt hopeless about the future; felt nervous or 
tense; worried too much about things; had trouble going to sleep or staying asleep; 
felt unhappy, sad or depressed. Response choices included never, rarely, sometimes, 
and often scored 1, 2, 3, and 4, respectively. An average of the scores was computed, 
resulting in values that ranged from 1 to 4. Scores across survey cycles 17-20 were 
averaged. In addition to the depression score, in survey cycle 21, participants were 
asked if a health professional had ever diagnosed them with a mood disorder (i.e., 
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depression, bipolar disorder) (yes, no) or an anxiety disorder (i.e., phobia, fear of 
social situations, obsessive-compulsive disorder, panic disorder, generalized anxiety 
disorder) (yes, no).  
 Statistical Analysis 
The frequency distributions of the outcome variables were examined to 
ensure that they were normally distributed and to identify outliers. Their distributions 
were also examined according to each categorical variable. Frequency distribution of 
continuous variable and their mean, range and variance were used to detect 
implausible values and possible outliers. The sample was stratified by sex and 
described according to socio-demographic and lifestyle characteristics. Cannabis use, 
change in BMI, and change in WC were examined according to socio-demographic 
and lifestyle characteristics in each group. Mean change in BMI and WC for each sex 
was plotted by frequency of cannabis use. In order to accommodate the U-shaped 
association between cannabis use and change in adiposity indicated by the figures 
(Appendix 1: Figure A.1 to Figure A.4), a quadratic term was created for cannabis use. 
The crude association was further examined in polynomial linear regression models 
of change in BMI or WC regressed on cannabis use and cannabis use squared. 
Accordingly, the models included interaction terms for “cannabis use and cigarette 
smoking”, and “cannabis use squared and cigarette smoking”.  
Potential confounders of the association between cannabis use and change in 
BMI or change in WC included sedentary behavior, physical activity, alcohol use, 
anxiety and depression diagnosis, depression symptoms and maternal education. 
These potential confounders were selected based on a correlation matrix as those 
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variables that were correlated at r ≥0.2 with cannabis use. Among male participants, 
alcohol use was the only variable correlated with cannabis use at this level. In female 
participants, none of the covariates examined were correlated with cannabis use at 
this level. However, although not correlated at r ≥0.2, physical activity and sedentary 
behavior were included in the models for both males and females since these 
variables are widely believed to be associated with adiposity. BMI and WC in survey 
cycle 19 were also included as covariates in the model. 
The statistical significance of all beta coefficients in the model was 
determined using the Wald test. To test the statistical significance of the interaction 
terms (i.e., “cannabis use and cigarette smoking”, and “cannabis use squared and 
cigarette smoking”), a full model (including both interaction terms) was compared to 
a reduced model (excluding the two interaction terms) using a likelihood ratio test. 
Multicollinearity between the cannabis use beta coefficients was expected as a 
result of a high level of correlation between cannabis, cannabis use squared, cigarette 
smoking, “cannabis use and cigarette smoking”, and “cannabis use squared and 
cigarettes smoking”. The variance inflation factors (VIFs) of these interaction terms 
exceeded ten, indicating a high level of multicollinearity. To reduce the potential for 
multicollinearity, values for cannabis use and cigarette smoking were centered 
around the mean value for cannabis use and the mean value for number of cigarettes 
smoked per day respectively. Sensitivity analyses were undertaken to ensure that the 
choice of the constant was appropriate by ensuring that centering by different 
constants did not have an impact on the value of the beta coefficient. The variance 
inflation factors (VIFs) of the resulting models were acceptable (VIF<6).  
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The residuals of each model were examined to ensure that model assumptions 
were met, to identify outlying residuals and to assess the stability of the model. 
Potentially outlying values were re-examined and their influence on the model 
assessed. Influential values were examined using Cook’s Distance and Leverage 
values. The influence of large values on the coefficients was analyzed. 
Because interpretation of a polynomial regression with an interaction term 
and centered variables is challenging, we plotted the association between cannabis 
use and change in BMI and WC in each final model for two hypothetical individuals 
– one who smoked half a cigarette per day, and one who smoked 15 cigarettes per 
day. Finally, a three dimensional graphing tool was used to identify the approximate 
stationary points of the curve in models containing an interaction term and 
rearrangement of the model equations used to determine its value.  
Results  
Most male participants (93%) were born in Canada; 72% spoke a language 
other than French (primarily English); and 53% had university-educated mothers 
(Table IV, p.65). Seventy-nine percent had a BMI <25, 60% were non-smokers and 
most drank alcohol occasionally to weekly (38%). Similarly, most female 
participants (94%) were born in Canada; 69% spoke a language other than French 
(primarily English); and 45% had university-educated mothers. Most female 
participants (84%) had BMI < 25, 54% were non-smokers and 53% drank alcohol 
occasionally to weekly.  
Table IV (p.27) reports cannabis use frequency according to selected socio-
demographic and lifestyle-related characteristics in males and females. The results 
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suggest that in males, a higher proportion of participants who did not speak French 
(i.e. who spoke English primarily) used cannabis; while, in females, a higher 
proportion of participants who spoke French used cannabis. In both males and 
females, the frequency of cannabis use increased with increased number of cigarettes 
smoked per day and decreased physical activity. In addition, in males, the frequency 
of cannabis use increased as the frequency of alcohol use increased. Finally, in both 
males and female participants, regular cannabis users (defined as weekly or more) 
were all born in Canada. The unadjusted mean change in BMI differed significantly 
across cannabis use in both male and female participants (Table V, p.67). Change in 
WC was not statistically significantly different across cannabis use in either sex. 
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Table IV: Cannabis use by selected socio-demographic and lifestyle-related characteristics in males and females. NDIT Study, 2005-2012 
 Male Female 
 Cannabis use (times per week) 
 
0 0.1 0.4 3 7 0 0.1 0.4 3 7 
n=152 
(56%) 
n=46 
(17%) 
n=22 
(8%) 
n=25 
(9%) 
n=26 
(10%) 
n=181 
(57%) 
n=65 
(20%) 
n=23 
(7%) 
n=31 
(10%) 
n=19 
(6%) 
% % % % % % % % % % 
French-speaking 32 26 26 20 15 33 20 44 23 42 
Born in Canada 92 89 96 100 100 91 99 96 100 100 
Mother university-educated 48 67 48 64 46 42 59 39 38 47 
BMI (kg/m
2
)           
<25 78 85 78 80 73 82 89 87 87 79 
≥25 >30 16 13 13 16 23 13 8 4 10 11 
       ≥30 6 2 9 4 4 5 3 9 3 11 
WC (cm) ≤ median 49 47 52 60 46 51 54 55 42 40 
No. cigarettes smoked/day           
Non users 78 52 35 24 19 68 52 35 23 11 
1
st
 tertile 11 30 17 12 8 14 21 22 20 16 
2
nd
 tertile  4 11 39 32 35 10 17 22 33 26 
3
rd
 tertile 7 7 9 32 39 9 11 12 23 47 
Sedentary behavior ≤ median 46 52 44 54 39 49 56 44 37 50 
Physical activity ≤ median 49 54 44 56 58 52 39 61 57 63 
Alcohol use           
   Non drinkers 51 35 9 20 15 39 11 13 13 5 
   Occasional to weekly 39 46 64 56 50 57 77 65 73 84 
   Weekly to daily 10 20 27 24 34 4 12 22 13 11 
Notes: BMI was categorized based on normal weight, overweight and obese BMI categories. Waist circumference, sedentary behavior and physical activity were categorized 
according to the median, which were 73.3 cm, 2.9 hours/day and 7.5 times/week respectively for female participants and  77.6 cm, 3,6 hours/day and 9.5 times/week for male 
participants. Number of cigarettes per day was categorized according to tertile in smokers: for female participants defined by 0.8 and 4.2 cigarettes per day and for male 
participants 0.7 and 5.7 cigarettes per day. Alcohol use was categorized according to past month frequency: 0 times/month non-drinkers, 0.1-7.9 times/month occasional to weekly, 
<8 times/month weekly/daily. 
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Table V: Body mass index (BMI) and waist circumference (WC) in males and females at age 17 and 24 years on average, and change in BMI and WC between 
age 17 and 24 years according to cannabis use. NDIT Study, 2005-2012. 
Cannabis use 
(times/wk) 
Age 17 
Mean (sd) 
Age 24  
Mean (sd) 
Change age 
17- 24 
Mean (sd) 
p-value 
Age 17 
Mean (sd) 
Age 24  
Mean (sd) 
Change from 
age 17- 24 
Mean (sd) 
p-value 
 
Male Female 
 BMI (kg/m
2
) 
(n=271) 
BMI (kg/m
2
) 
(n=319) 
Total  22.8 (3.8) 24.8(4.1) 2.0(2.5)  22.1(3.9) 23.7(4.6) 1.5(2.5)  
0 22.9(3.9) 25.5(4.4) 2.5(2.4) 0.002 22.2(3.6) 24.2(4.8) 1.8(2.6) 0.036 
0.1 22.5(2.9) 24.4(3.6) 1.9(2.2)  21.5(3.6) 22.6(3.2) 1.1(2.4)  
0.4 23.2(4.1) 23.9(3.2) 0.8(1.8)  22.1(3.7) 22.8(4.3) 0.7(1.6)  
3 22.1(4.5) 23.4(4.1) 1.3(3.3)  22.0(3.4) 22.8(4.2) 0.8(1.9)  
7 22.9(3.9) 24.0(3.6) 1.1(2.5)  23.5(7.6) 24.8(7.0) 1.3(2.9)  
 WC (cm) 
(n=250) 
WC (cm) 
(n=283) 
Total 79.8(9.4) 85.8(10.5) 5.8(7.2)  75.8(9.6) 77.6(11.3) 1.8(7.2)  
0 80.0(9.3) 86.8(10.9) 6.9(7.3) 0.066 75.6(9.2) 78.1(11.8) 2.5(7.8) 0.276 
0.1 78.4(6.3) 84.5(9.2) 5.0(6.6)  75.4(9.4) 76.2(9.4) 0.9(6.2)  
0.4 80.5(10.7) 83.9(10.2) 2.6(3.9)  75.8(9.9) 76.5(11.8) 0.8(6.9)  
3 79.6(11.1) 83.9(10.9) 4.5(9.0)  77.1(9.0) 76.4(8.6) -0.1(6.6)  
7 81.1(11.6) 86.0(9.8) 5.0(7.3)  78.1(15.7) 81.2(15.7) 2.9(5.7)  
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Males 
The interaction terms,  “cannabis use and cigarette smoking”, and “cannabis 
use squared and cigarette smoking”, were statistically significant as was their joint 
effect in the BMI model (p=0.004)  (Table VI, p.70; Appendix 2: Figure A. 6). In the 
WC model, the interaction term “cannabis use squared and cigarette smoking” was 
statistically significant, as were the combined pair of interactions (p=0.036) (Table 
VI, p.70; Appendix 2:Figure A. 6). In both models, the association between cannabis 
use and change in adiposity was U-shaped in non-smokers. In smokers, the plot 
became an inverted U-shape with increasing cigarette smoking (Figure 5.1 p.71). 
More specifically, among non-smokers, the adjusted mean change in BMI in 
cannabis non-users, weekly cannabis users and daily cannabis users was 2.4 
kg/m
2
(2.4,2.4), -0.2 kg/m
2
(-0.2,-0.1) and 1.1 kg/m
2
(-0.0,2.1), respectively. For 
hypothetical male participants who smoked 0.5 cigarettes per day, the predicted mean 
change in BMI in cannabis non-users, weekly cannabis users, and daily cannabis 
users was 2.4 kg/m
2
(2.3,2.4), -0.1 kg/m
2
(-0.1,0.0) and 1.1 kg/m
2
(-0.2,2.3), 
respectively (Figure 5.1 p.71). For hypothetical male participants who smoked 15 
cigarettes per day, the predicted mean change in BMI in cannabis non-users, weekly 
cannabis users, and daily cannabis users was 2.1 kg/m
2
(1.9,2.4), 3.0 kg/m
2
(2.5,3.5) 
and 1.6 kg/m
2
(-5.1,8.5), respectively (Figure 5.1 p.71). 
Similarly, among non-smokers, the adjusted mean change in WC among 
cannabis non-users, weekly cannabis users, and daily cannabis users was: 6.2cm (6.1, 
6.2), 1.5cm (1.3,1.7) and 5.5cm (2.5,8.3) respectively. For hypothetical male 
participants who smoked 0.5 cigarettes per day, the predicated mean change in WC 
among cannabis non-users, weekly cannabis users, and daily cannabis users was 
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6.3cm (6.2,6.4), 1.9cm (1.6,2.1) and 5.5cm (2.0,9.0), respectively (Appendix 2: 
Figure A.3). The predicted mean change in WC for hypothetical male participants 
who smoked 15 cigarettes per day for cannabis non-users, weekly cannabis users, and 
daily cannabis users was: 8.2cm (7.1,9.3), 11.4cm (9.7,13.1) and 7.0cm (-14.9,29.0), 
respectively (Appendix 2: Figure A.3).  
Three dimensional graphs of the models indicated that a stationary point 
existed at the intersection of the slopes of cigarette use and change in BMI or change 
in WC for cannabis non-users and weekly cannabis users. Solving the equations 
identified the point at which the association between cannabis use and change in BMI 
or change in WC flattened. For the model fitted to change in BMI, the point of 
intersection was at approximately 7 cigarettes per day, and for the model fitted to 
change in WC it was at approximately 10 cigarettes per day.  
Females 
Neither of the interaction terms, “cannabis use and cigarette smoking” or 
“cannabis use squared and cigarette smoking”, were statistically significant in either 
the model for BMI or the model for WC in female participants. Although the beta 
coefficients for cannabis use and cannabis use squared were statistically significant 
(p=0.016 and, p=0.035, respectively) in the model testing change in BMI, the beta 
coefficients predicting change in WC were not statistically significant (p=0.149, and 
p=0.055, respectively). However, similar to the models for male non-smokers, the 
association between cannabis use and change in BMI was U-shaped. The adjusted 
mean change in BMI among cannabis non-users, weekly cannabis users, and daily 
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cannabis users were: 1.6 kg/m
2
(1.5, 1.6), 0.4 kg/m
2
(0.2,0.6) and 1.3 kg/m
2
 (-1.6,4.1), 
respectively (Figure 5.2, p.71).  
 
 
 
Table VI: Beta coefficients and 95% confidence intervals for the association between cannabis use (CU) 
and change in body mass index (BMI) ( kg/m2)  and change in waist circumference (WC) (cm) in male 
and female participants. NDIT Study 2005-2012 
 Change in BMI(kg/m
2
) Change in WC (cm) 
 Male 
 Model 1  
β (95% CI) 
Model 2
†
  
β (95%CI) 
Model 3
†
  
β (95%CI) 
Model 1  
β (95% CI) 
Model 2
†
  
β (95% CI) 
Model 3
†
  
β (95% CI) 
CU -0.33* 
(-0.55,-0.11) 
-0.41* 
(-0.63,-0.18) 
-0.35* 
(-0.58,-0.13) 
-0.28 
(-0.95,0.38) 
-0.68 
(-1.14,0.02) 
-0.47 
(-1.20,0.26) 
CU*CU 0.07 
(-0.02,0.15) 
0.09* 
(0.00,0.17) 
0.08 
(-0.00,0.16) 
0.061 
(-0.20,0.32) 
0.16 
(-0.09,0.41) 
0.14 
(-0.11,0.40) 
Cigarette 
smoking 
 0.06 
(-0.00, 0.11) 
0.18* 
(0.08,0.28) 
 0.31* 
(0.11,0.50) 
0.60* 
(0.31,0.90) 
Cigarette 
smoking*
CU 
  0.05* 
(0.02,0.08) 
  0.11 
(-0.00,0.22) 
Cigarette 
smoking* 
CU*CU 
  -0.02* 
(-0.03,-0.01) 
  -0.05* 
(-0.08,-0.01) 
 Female 
Model 1  
β (95% CI) 
Model 2  
β (95% CI) 
Model 3  
β (95% CI) 
Model 1  
β (95% 
CI) 
Model 2  
β (95% 
CI) 
Model 3  
β (95% CI) 
CU -0.23* 
(-0.43,-0.02) 
-0.26* 
(-0.47,-
0.05) 
-0.30* 
(-0.52,-
0.07) 
-0.47 
(-
1.16,0.23) 
-0.52 
(-
1.23,0.19) 
-0.73 
(-1.47,0.02) 
CU*CU 0.07 
(-0.01, 0.16) 
0.09* 
(0.01,0.17) 
0.10* 
(0.01,0.18) 
0.24 
(-
0.04,0.52) 
0.27 
(-
0.01,0.55) 
0.32* 
(0.04,0.60) 
Cigarette 
smoking 
- 0.01 
(-0.06,0.08) 
0.01 
(-0.12,0.12) 
- 0.06 
(-
0.16,0.27) 
-0.15 
(-0.51,0.21) 
Cigarette 
smoking*
CU 
- - -0.02 
(-0.06,0.02) 
- - -0.10 
(-0.23,0.02) 
Cigarette 
smoking* 
 CU*CU 
- - -0.00 
(-0.01,0.01) 
- - 0.03 
(-0.06,0.07) 
Model 1: unadjusted. Model 2: model adjusted for the baseline level of BMI or WC, physical activity 
and sedentary behavior. Model 3: model adjusted for the baseline level of BMI or WC, physical activity, 
and sedentary behavior. 
†
For alcohol use. * p<0.05 
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Figure 5.1: Predicted change in BMI (kg/m
2
) (95% confidence interval) according to cannabis use 
among hypothetical male participants who smoked 0.5 and 15 cigarettes per day, respectively 
 
Figure 5.2: Predicted change in BMI (kg/m
2
) (95% confidence interval) in female participants by 
cannabis use  
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Discussion  
This study partially supports our hypothesis that cannabis use is associated with 
changes in adiposity (and more specifically with weight gain), and that this 
association is modified by cigarette smoking. As expected based on the literature, the 
association between cannabis use and change in adiposity differed between male and 
female participants. Among males, the association between cannabis use and change 
in adiposity was modified by cigarette smoking. A U-shaped association was 
observed among male non-smokers, while an inverted U-shaped association was 
observed in males who smoked more than approximately ten cigarettes per day. 
Among male participants, the smallest change in adiposity was observed among 
weekly cannabis users who were non-smokers; while, the largest change was 
observed in weekly cannabis users who smoked the most cigarettes.  
In contrast, in females, neither of the interaction terms tested was statistically 
significant in either the model predicting change in BMI or the model predicting 
change in WC. Thus, it appears that the association between cannabis use and change 
in adiposity is not modified by cigarette smoking in females. The reduced models 
predicting change in BMI and change in WC according to cannabis use suggested a 
U-shaped association in females. However, only the model predicting change in BMI 
by cannabis use was statistically significant (p<0.05). Among females, the smallest 
change in BMI and WC was observed among weekly cannabis users. To the best of 
our knowledge this is the first time a population-based study has tested for effect 
modification in the association between cannabis use and change in adiposity by 
cigarette smoking in males and females. 
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The ECS is the biological framework used in this study to underpin our 
hypotheses about the association between cannabis use and change in adiposity and 
its interaction with cigarette smoking. The role of the ECS in energy homeostasis and 
its importance in regulation of feeding via hormones of the hypothalamus, have been 
documented and over-activation of the ECS is suggested as a potential cause of 
overweight and obesity (14, 16, 31, 33). In females and in male non-smokers who use 
cannabis three times a week or more, a positive association between cannabis use and 
change in adiposity is observed, which is consistent with studies that have 
demonstrated the orexogenic effect of cannabis. Our results are also consistent with 
studies that demonstrate that the effect of the ECS on energy homeostasis differs 
according to sex at a cellular level and at the endocrine level due to an interaction 
with the sex hormones (10-12). The homeostatic effects of the ECS have been found 
to be more apparent in males, while its effects on mood, particularly anxiety, are 
more apparent in females (10).  
Two literature reviews that synthesized findings on the joint effects of 
cannabis and cigarette smoking identified cigarette smoking as an important modifier 
of the effects of cannabis use on the functioning of the ECS (19, 20). Most of the 
studies included in these reviews however, were animal studies and their applicability 
to human populations is not known. Contrasting and parallel effects of THC and 
nicotine highlighted in these reviews include their action on the reward system, 
substance initiation, cessation of substance use, and appetite (19, 20). The male-
specific interaction between cannabis use and cigarette smoking observed in our 
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study partially supports the conclusions of these reviews and extends their 
applicability to the human population.  
Population-based studies have examined the association between cannabis use 
and adiposity. In particular, two longitudinal studies have examined cannabis use and 
change in adiposity, but obtained conflicting results (24, 81). One study which was 
conducted in 1976 under ward condition (i.e., participants (all of whom were male) 
were restricted to a hospital area) showed that heavy cannabis users gained an 
average of 3.7 pounds (lbs), casual users gained 2.8 lbs and controls gained 0.2 lbs 
over a 21-day period of unlimited voluntary cannabis exposure (24). These results 
however should be interpreted with caution given the date of the study and the lack of 
replication of its findings. The other longitudinal study was the Coronary Artery Risk 
Development in Young Adults (CARDIA) study, which examined self-report 
cannabis use in relation to measured height, weight and WC controlling for gender, 
race, age, alcohol use, daily physical activity, physical fitness, education, income 
level and cigarette smoking. No independent association was observed between 
cannabis use and BMI or WC (81). This study did not consider possible sex 
differences in the association, nor did it examine possible effect modification of the 
association by cigarette smoking. Cross-sectional studies examining the association 
between cannabis use and BMI have generally shown either a negative or null 
association (4, 21-23, 25), and most of these studies also did not consider effect 
modification of the association by sex or by cigarette smoking.  
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Proposed mechanism 
 Three results of this study are particularly noteworthy. First, cigarette 
smoking in males modifies the association between cannabis use and change in 
adiposity. Second, there is a U-shaped association between cannabis use and change 
in adiposity in male non-smokers.  Third, there is a U-shaped association between 
cannabis use and change in adiposity in females, which is statistically significant in 
the model fitted to change in BMI, but not in the model fitted to change in WC.  
Physiological differences between the sexes at the level of the POMC synapse 
may explain the observed male-specific interaction (10). These synapses potentiate 
differently in male and female animals such that CB1 activation result in increased 
excitation in females and in inhibition in males (10). POMC synapses are also 
influenced by nicotine through a nicotine receptor located on its membrane (98). It is 
therefore possible that nicotine and THC have interacting effects at the level of the 
POMC neurons in males, but not in females since CB1 receptor density varies with 
the oestrous cycle in females and thus, may be more finely regulated (12). Further 
research is required to understand the sex specific interaction observed. 
There is a U-shaped association between cannabis use and change in adiposity in 
male non-smokers, with the smallest change in adiposity observed in weekly 
cannabis users. Increased cannabis use among regular cannabis users (defined as 
weekly or more) may be associated with increased change in adiposity. Physiological 
data suggests that an increase in activity of the ECS results in increased appetite via 
the hypothalamus and its hormones such as leptin and NPY that are involved in 
digestion (16, 33). However, the U-shaped association observed in our study also 
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suggests that, compared to cannabis non-users, regular cannabis users have a smaller 
increase in adiposity. Genetic, neurobiological, social or behavioral differences in 
these two groups, rather than the difference in cannabis use, may explain these 
results. Given the expansive nature and role of the ECS in the body and the novelty 
of its discovery, an unknown confounder may have contributed to residual 
confounding of the association of interest.  
The U-shaped association observed in this study may also be indicative of a 
hormesis phenomenon – a term used to describe an association in which the outcome 
is under homeostatic control and a physiological overcompensation occurs in 
response to an external stress in an effort to re-establish homeostasis (99). It can be 
hypothesized that at the periphery, stimulation by cannabinoids results in fat 
deposition and adipocyte differentiation, which are under negative feedback 
regulation by leptin (29). In weekly cannabis users, THC remains in the body stored 
in fat tissue and continues to stimulate the peripheral ECS (12). The increased 
peripheral adipose activity could result in increased leptin production which would 
decrease central energy storage behaviors. In daily users, high central and peripheral 
cannabinoid levels resulting from acute THC exposure would result in balanced 
down-regulation by leptin of peripheral and central endocannabinoids, and therefore 
no net change in adiposity would ensue. This hypothesis suggests that low levels of 
cannabis use may protect against increased weight gain in young adults.  
Finally, the association between cannabis use and adiposity in females is U-
shaped and only statistically significant in the model predicting change in BMI. Why 
the association differs between the WC and BMI models is unclear. The crude mean 
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change in WC (1.8cm) and its variance (7.5cm) in females suggests that the high 
variability of this measure may underpin the difference observed. In comparison, the 
mean change in BMI in females was of a similar magnitude (1.5 kg/m
2
) with a 
smaller variance (2.5 kg/m
2
). The proposed mechanisms for the U-shaped association 
between cannabis use and change in BMI in females may be similar to those 
described earlier for male non-smokers.  
Limitations  
The main limitation of this study is the self-report measure of cannabis use 
which may have resulted in information bias. Although we used a five point Likert-
type response scale comparable to measures used in other population-based studies, 
its validity and reliability in the Canadian population is not known. A validation 
study was commissioned by the National Survey of Drug Use and Health in 2000-
2001 in the U.S. that reports that the overall congruence between past-month recall 
and urinalysis is 90% (kappa=0.517, p<0.001) (100). However, these results were 
likely an over-estimation due to use of a population in which drug prevalence was 
low and its assumption that all individuals denying marijuana use in the past month 
and testing negative had in fact not used marijuana (101). No validation study has yet 
been conducted in Canada. Given the illicit nature of cannabis, cannabis use may 
have been under-reported.  
Another possible source of information bias relates to the lack of data on mulling 
(i.e., mixing tobacco and cannabis together prior to smoking), which has not been 
quantified in North America. While mulling is a common practice in Europe,  the 
extent to which cannabis users who do not smoke cigarettes are exposed to tobacco in 
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Canada remains unknown (88). If non-cigarette smoking cannabis users were 
exposed to tobacco through mulling, the associations observed would likely have 
been attenuated.  
Finally, residual confounding may have biased the associations of interest. 
Genetics may differ in ECS at a receptor or signaling molecule level, thus altering 
both the homeostatic regulation of energy and the pre-disposition to cannabis use. 
Participants who smoke cannabis may control their weight more closely than those 
who do not use cannabis. Cannabis users may use greater amounts of other 
substances (i.e. other illicit drugs) that may alter energy homeostasis. Although the 
literature suggests that diet varies by both outcome and exposure, in the conceptual 
model used for this study, changes in diet as a result of cannabis use were viewed as 
being on the causal pathway between cannabis use and change in adiposity and was 
therefore excluded as a covariate. Age was also excluded from the analysis, since the 
cohort was from the same academic grade and therefore, there was little variability in 
age. 
Conclusion 
This study suggests that the association between cannabis use and change in 
adiposity is modified by cigarette smoking in males, but not in females. More 
specifically, the association was U-shaped in males who do not smoke cigarettes, 
while in male smokers, the association was an inverted U-shape. Male non-smokers 
who use cannabis weekly had the smallest adjusted change in adiposity. The largest 
change in adiposity was observed in weekly cannabis-users who also smoke 
cigarettes. Cannabis use in females was associated with change in adiposity in a U-
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shaped relationship, with weekly cannabis users having the smallest adjusted change. 
This association was only statistically significant in the model predicting change in 
BMI. Increasing regular cannabis use was associated with an increased BMI, 
although the greatest increase in BMI was observed among cannabis non-users.  
  
Chapter 6: Discussion  
6.1. Summary of results  
This study partially supports our hypotheses that cannabis use is associated with 
greater increases in adiposity over time; and that the association between cannabis 
use and change in adiposity is modified by cigarette smoking. The association 
between cannabis use and change in adiposity in males was modified by cigarette 
smoking. A U-shaped association was observed between cannabis use and change in 
adiposity in male non-smokers, while an inverted U-shaped association was observed 
in males who smoked more than approximately 10 cigarettes per day. The smallest 
change in adiposity was observed in male non-smokers who use cannabis weekly; 
while, the greatest change in adiposity was observed in males who used cannabis 
weekly and were smokers. 
In contrast, in females, neither of the interaction terms tested was statistically 
significant in either the model predicting change in BMI or the model predicting 
change in WC. Thus, it appears that the association between cannabis use and change 
in adiposity is not modified by cigarette smoking among females. The reduced 
models (i.e., without the interaction terms) predicting change in BMI and change in 
WC according to cannabis use demonstrated a U-shaped association in females. 
However, only the model predicting change in BMI by cannabis use was statistically 
significant (p<0.05). Among females, the smallest change in BMI and WC was 
observed among weekly cannabis users.  
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6.2. The results in context  
The ECS is the biological framework within which we conceptualized the 
association between cannabis use and change in adiposity, and its interaction with 
cigarette smoking. Studies examining the functions of the ECS in energy homeostasis 
demonstrate its role in the regulation of feeding via hormones of the hypothalamus, 
and have identified over-activation of the ECS as a potential cause of overweight and 
obesity (14, 16, 31, 33). The positive association between cannabis use and change in 
adiposity in females and in male non-smokers who use cannabis regularly is 
consistent with studies that report the orexogenic effect of cannabis use.  
The functioning of the ECS differs according to sex at a cellular level and at 
the endocrine level due to an interaction with the sex hormones (10-12). Its 
homeostatic effects have been found to be more notable in males, while its effects on 
mood, particularly anxiety, are more notable in females (10). Two literature reviews 
that synthesized the joint effects of cannabis and cigarette smoking identified 
cigarette smoking as an important modifier of the effects of cannabis use on the ECS 
(19, 20). Most studies included in these reviews were animal studies and their 
applicability to human populations is not known. Contrasting and parallel effects of 
THC and nicotine highlighted in these reviews include their action on the reward 
system, substance initiation, cessation of substance use, and appetite (19, 20). The 
male-specific interaction between cannabis use and cigarette smoking observed in 
our study partially supports the conclusion of these reviews and extends their 
applicability to the human population.  
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Population-based studies have examined the association between cannabis use 
and adiposity. In particular, two longitudinal studies examined the association 
between cannabis use and change in adiposity, and obtained conflicting results (24, 
81). One study which was conducted in 1976 under ward condition (i.e., participants 
(all of whom were male) were restricted to a hospital area) showed that heavy 
cannabis users gained an average of 3.7 pounds (lbs), casual users gained 2.8 lbs and 
controls gained 0.2 lbs over a 21-day period of unlimited voluntary cannabis 
exposure (24). These results should however be interpreted with caution given the 
date of the study and the lack of replication of the findings.  
The second longitudinal study was the Coronary Artery Risk Development in 
Young Adults (CARDIA) study, which examined self-report cannabis use in relation 
to measured height, weight and WC, controlling for gender, race, age, alcohol use, 
daily physical activity, physical fitness, education, income levels and cigarette 
smoking. No independent association was observed between cannabis use and BMI 
or WC (81). This study did not examine possible effect modification of the 
association by sex or by cigarette smoking. Cross-sectional studies examining the 
association between cannabis use and BMI have generally shown either a negative or 
null association (4, 21-23, 25). Most of these studies also did not consider effect 
modification of the association by sex or by cigarette smoking.  
6.3. Proposed mechanism 
Three results of this study are particularly noteworthy. First, cigarette smoking in 
males modified the association between cannabis use and change in adiposity. 
Second, there was a U-shaped association between cannabis use and change in 
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adiposity in male non-smokers.  Third, there was a U-shaped association between 
cannabis use and change in adiposity in females, which is only statistically significant 
in the model fitted to change in BMI.  
Physiological differences between the sexes at the level of the POMC synapse 
may explain the observed male-specific interaction (10). These synapses potentiate 
differently in male and female animals such that CB1 activation results in increased 
excitation in females and in inhibition in males (10). POMC synapses are also 
influenced by a nicotine through a nicotine receptor located on its membrane (98). It 
is therefore possible that nicotine and THC have interacting effects at the level of the 
POMC neurons in males, but not in females since CB1 receptor density varies with 
the oestrous cycle and thus, may be more finely regulated in females (12). Further 
research is required to understand the sex interaction observed.   
There was a U-shaped association between cannabis use and change in adiposity 
in male non-smokers, with the smallest change in adiposity observed in weekly 
cannabis users. Increased cannabis use among regular cannabis users (defined as 
weekly or more use) may be associated with increased change in BMI and WC. 
Physiological data suggests that an increase in activity of the ECS results in increased 
appetite via the hypothalamus and its hormones such as leptin and NPY that are 
involved in digestion (29, 33). However, the U-shaped association observed in our 
study suggests that, compared to cannabis non-users, regular cannabis users have a 
smaller increase in adiposity. Genetic, neurobiological, social or behavioral 
differences between these two groups, rather than the difference in cannabis use, may 
explain these results. Given the expansive nature and role of the ECS in the body and 
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the novelty of its discovery, an unknown confounder may have contributed to 
residual confounding of the association of interest. 
The U-shaped association observed in this study may be indicative of a hormesis 
phenomenon – a term used to describe an association in which the outcome is under 
homeostatic control and a physiological overcompensation occurs in response to an 
external stress in an effort to re-establish homeostasis (99). It could be hypothesized 
that at the periphery, stimulation by cannabinoids results in fat deposition and 
adipocyte differentiation, which are under negative control by leptin (29). In weekly 
cannabis users, THC remains in the body stored in fat tissue and continues to 
stimulate the peripheral ECS (12). The increased peripheral adipose activity could 
result in increased leptin production which would decrease central energy storage 
behaviors. In daily users, high central and peripheral cannabinoid levels resulting 
from acute THC exposure would result in balanced down-regulation by leptin of 
peripheral and central endocannabinoids, and therefore no net change in adiposity 
would ensue. This hypothesis suggests that low levels of cannabis use may protect 
against increased weight gain in young adults. If this were the case, the long term 
effects of an overstimulation of leptin production should be examined.  
Finally, the association between cannabis use and adiposity in females is U-
shaped, and only significant in the model predicting change in BMI. Why the 
association differs between WC and BMI is unclear. The crude mean change in WC 
(1.8cm) and its variance (7.5cm) in females suggests that the high variability in this 
measure may underpin the difference. In comparison, the mean change in BMI in 
females was of a similar magnitude (1.5 kg/m
2
) with a smaller variance (2.5 kg/m
2
). 
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The proposed mechanisms for the U-shaped association between cannabis use and 
change in BMI in females may be similar to those described earlier for male non-
smokers.  
6.4. Limitations   
This study was conducted as a secondary analysis of the larger NDIT study, 
the objectives of which did not include the objectives of this thesis. This analysis was 
therefore limited by the design of, and variables available in this larger data set. Its 
external validity was limited to the Montreal, Quebecois or Canadian young adult 
population due to the use of a convenience sample. However, efforts were made to 
ensure that the schools selected were representative of a diverse population.  
The design of this study represents an unconventional straddling of the 
exposure by the baseline and final measures of the outcome variables as a 
consequence of the data available. Although this is atypical, the mean age of 
initiation to cannabis use in this population occurred prior to the first exposure and 
baseline outcome measure.  
The main limitation of this study is the self-report measure of cannabis use 
which may have resulted in information bias. Although we used a five-point Likert-
type response scale that is comparable to measures used in other population-based 
studies, its validity and reliability within the Canadian population is not known. The 
external validity of the studies outlined next is unknown since policies, law 
enforcement and social acceptability of cannabis use is differs by region.  
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Two studies were identified that compared test-retest reliability of self-report 
cannabis use. One study reported excellent test-retest concordance between self-
report questions concerning lifetime, past-year and past-month cannabis use 
answered by Italian youth (aged 15-19) (Cohen’s k= 0.862), which increased with 
age (102). Another study observed high concurrent validity between past six-months 
self-reported drug use and individuals’ self-report Timeline Followback measure of 
use, a well-validated measure of illicit drug use, and the report of a spouse (98% and 
86% agreement, respectively) (103). The sample of this study consisted of U.S. 
adults receiving couples treatment for one of the individual’s alcohol problems. 
Three studies compared self-report cannabis use measures to urinalysis 
measures. One study  conducted in Chicago men (age 18-40 years) from the general 
population reported excellent concordance between a positive urine test and self-
reported past-month marijuana use (kappa= .85) (104). A second study conducted in 
248 U.S. adolescents observed only moderate concordance between urinalysis and 
self-reported measures (kappa=0.4) (105). Finally, a validation study was 
commissioned by the National Survey of Drug Use and Health in 2000-2001 in the 
U.S. that reports that the overall congruence between past-month recall and urinalysis 
is 90% (kappa=0.517, p<0.001) (100). These results were likely an over-estimation 
due to use of a population in which drug prevalence was low and its assumption that 
all individuals denying marijuana use in the past month and testing negative had in 
fact not used marijuana (101). No validation study has yet been conducted in Canada. 
Given the illicit nature of cannabis in Canada, cannabis use may have been under-
reported in our study. 
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Another possible source of information bias relates to the lack of data on 
mulling (i.e., mixing tobacco and cannabis together prior to smoking), which has not 
been quantified in North America. While mulling is a common practice in Europe,  
the extent to which cannabis users who do not smoke cigarettes are exposed to 
tobacco in Canada remains unknown (88). If cannabis users who do not smoke 
cigarettes were exposed to tobacco through mulling, the associations observed in our 
study would likely have been attenuated.   
The quality of the outcome measures, change in BMI and change in WC, are 
a strength of this study as a result of the standardized protocol used to collect them 
(50). The 189 imputed missing baseline BMI values reduced the quality of the BMI 
outcome measure, since these values were imputed from later self-report measures. 
However, in participants who were not missing measured BMI values, a high 
correlation was observed between the values predicted using self-report measures and 
their measured values. 
Finally, residual confounding may have biased the associations of interest. 
Genetics may differ in ECS at a receptor or signaling molecule level, thus altering 
both the homeostatic regulation of energy and resulting in a pre-disposition to use 
cannabis. Participants who smoke cannabis may control their weight more closely 
than those who do not use cannabis. Finally, cannabis users may use greater amounts 
of other substances (i.e., other illicit drugs) that may alter energy homeostasis. 
Although the literature suggests that diet varies by both outcome and exposure in the 
conceptual model used for this study, changes in diet as a result of cannabis use may 
be on the causal pathway between cannabis use and change in adiposity and was 
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therefore excluded as a covariate. Age was also excluded from the analysis, since the 
cohort was from the same academic grade and therefore there was little variability in 
age. 
6.5. Public health implications   
The results of this thesis have public health implication related to the obesity 
pandemic and cannabis use. Although the mechanisms underpinning the associations 
observed have yet to be clarified, the results suggest that moderate cannabis use 
protects against weight gain, and may therefore have therapeutic potential in treating 
obesity. If this protective effect exists, the negative effects of cannabis use on health, 
particularly psychological, must be considered in any therapeutic strategy. In direct 
contrast, the results also indicate that regular cannabis use may be associated with 
increased weight gain. If cannabis use promotes weight gain, it may become a new 
target for obesity prevention and widespread dissemination of this information may 
discourage young adults who fear weight gain, from initiating cannabis consumption. 
If a U-shaped association between cannabis use and change in adiposity exists, it is 
possible to reconcile these contrasting results, by suggesting a “therapeutic” and a 
“toxic” range in cannabis use frequency. In such a case, synthetic cannabinoids could 
be used to treat obesity and cannabis could be targeted for prevention. The lack of 
research about the effects of cannabis use on health coupled with its widespread use 
is a major public health concern.  Public health approaches to cannabis use 
prevention among Canadians may be needed, especially in parts of Canada where 
more youth are smoking cannabis than cigarettes (61). In order to support a public 
health approach, further research is necessary and a public discussion concerning the 
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legality of the drug needs development. Its illicit nature may relate at least in part to 
the lack of information about its effects in the population.  
6.6. Future research   
This study underscores that further research on cannabis use in the North 
American population is essential. Several key elements remain unresolved before 
results of this study can be considered robust. First, future research must use valid 
and reliable measures of cannabis use. For large scale studies, comparison of self-
reports of cannabis use and urine tests in various age groups and regions is essential. 
Research is needed to quantify cigarette and cannabis co-use in the context of 
mulling or chasing. Does mulling occur as frequently in Canada as in Europe? Do 
individuals self-identify as tobacco smokers when they mull or chase? What are the 
patterns of use and simultaneous use? These issues need to be addressed in order to 
provide credibility to studies on cannabis use.  
Our results suggest several avenues for further research. If there is an interaction 
between cannabis use and cigarette smoking in males and not in females, what aspect 
of the ECS is responsible for this? Is the mechanism for the interaction in males 
based on change in receptor density, affinity or activity alteration? Is the interaction 
in males the result of THC and nicotine acting centrally or peripherally? Are there 
unidentified factors that differentiate cannabis users from non-users that are 
responsible for the U-shaped associations observed? Would our results be replicable 
with repeated and more accurate measures of cannabis use? Given the novelty of this 
area of research and the results of this study, these are only a few of the many 
questions that remain to be answered.   
  
Chapter 7: Conclusion   
The current study was prompted by evidence that cannabis use has an effect 
on energy homeostasis. In males only, the effect of cannabis use on change in 
adiposity was modified by cigarette smoking, such that a U-shaped association was 
observed in non-smokers. The association in male smokers was also U-shaped but 
flattened and inverted with increasing cigarette use. The smallest adjusted change in 
adiposity was observed in males who did not smoke and who used cannabis weekly. 
The largest adjusted change was observed in males who used cannabis weekly and 
were smokers. Regular cannabis use was associated with increased adiposity. 
However, the largest increase in adiposity was observed in cannabis non-users.  
In females, the association between cannabis use and change in adiposity was 
U-shaped. The association was statistically significant in the model predicting change 
in BMI, but not in the model predicting change in WC. In the BMI model, weekly 
cannabis users had the smallest adjusted change in BMI. Regular cannabis use was 
associated with increased BMI, although the largest increase in BMI was observed 
among cannabis non-users. Further population-based and neurobiological research is 
required to understand these differences in the associations across sex. It may also be 
necessary to consider exposure to cannabis in studies investigating the effects of 
cigarette smoking on energy homeostasis in males. 
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Appendix 1: NDIT questionnaire items for variables included in this thesis 
Item from the maternal questionnaire: 
 
1. What is the highest level of education that you have attained? 
 
   Attended high school, but did not graduate   
   Graduated from high school  
   Attended CEGEP, community college, or technical program, but did not graduate    
   Graduated from CEGEP, community college, technical program  
   Attended university but did not graduate  
   Graduated from university with a Bachelor degree  
   Graduated from university with a Master’s degree  
   Graduated from university with a PhD  
   Other (specify)__________ 
 
 
Items from survey cycles 1 to 20 questionnaires: 
 
2. In what month is your birthday? 
 
 January  July 
 February  August 
 March  September 
 April  October 
 May  November 
 June  December 
 
3. On what day of the month is your birthday? Circle the correct day. 
1 2 3 4 5 6 7 8 9 10  
11 12 13 14 15 16 17 18 19 20  
21 22 23 24 25 26 27 28 29 30 31 
 
4. In what year were you born? 
  1984 
  1985 
xxvii 
 
  1986  
  1987 
  1988  
  Other ____________________________________________ 
 Specify year 
 
5. How old are you today? Write the correct number in the box. 
  years 
 
6. Are you a…..? 
 Boy  Girl 
 
7. What language do you speak most often at home? Check ONE box. 
 English 
  French 
  French and English  
  Other ____________________________________________ 
 Specify 
 
8. Were you born...? 
 In Canada  ___________________________________ 
 Name province 
  Outside Canada  ______________________________ 
 
  Name country 
9. Now, think about the physical activities that you did last week from 
Monday to Sunday outside your regular school gym class.  For each 
activity that you did for 5 minutes or more at one time, mark an "X" to 
show the day(s) on which you did that activity. 
 Mon. Tues. Wed. Thur. Fri. Sat. Sun. 
Bicycling to school, bicycling to do errands, 
going for a bicycle ride 
       
Swimming/diving        
Basketball        
xxviii 
Baseball/softball        
Football        
Soccer        
Volleyball        
Racket Sports (badminton, tennis)        
Ice hockey/ball hockey        
Jump rope        
Downhill skiing, snowboarding        
Cross-country skiing        
Ice skating        
Rollerblading, skateboarding        
Gymnastics (bars, beams, tumbling, trampoline)        
Exercise / physical conditioning (push-ups, sit-
ups, jumping jacks, weight-lifting, exercise 
machines) 
       
Ball-playing (dodge ball, kickball, wall-ball, 
catch) 
       
Track and field        
Games (chase, tag, hopscotch)        
Jazz/classical ballet        
Dancing (aerobic, folk, at a party)        
Outdoor play (climbing trees, hide and seek)        
Karate/ Judo/ Tai Chi/ Kung Fu        
Boxing, wrestling        
Outdoor chores (mowing, raking, gardening)        
Indoor chores (mopping, vacuuming, sweeping)        
Mixed walking / running / jogging        
Walking        
Running/Jogging        
Other(s)  Name them        
a)        
xxix 
 
b)        
c)        
 
10. During the past 3 months, how often have you…? 
 
 Never Rarely Sometimes Often 
Felt too tired to do things     
Had trouble going to sleep or staying 
asleep 
    
Felt unhappy, sad, or depressed     
Felt hopeless about the future     
Felt nervous or tense     
Worried too much about things     
 
11. During the past 3 months, how often did you…? 
 
Never A bit to 
try 
Once or 
a couple 
of times 
a month 
Once or a 
couple of 
times a 
week 
Usually 
every 
day 
Drink alcohol (beer, wine, hard 
liquor)      
 
12. How many hours of television (including video movies) do you usually watch in a 
single day? If the answer is zero, write “0” in the box. If the answer is less than ½ 
hour, write “LT ½”. 
 
On weekdays, I usually watch  
hour(s) of television a day 
 
   
On weekends, I usually watch  
hour(s) of television a day 
 
 
13. How many hours do you usually play video or computer games, or use the 
Internet in a single day? If the answer is zero, write “0” in the box. If the 
answer is less than ½ hour, write “LT ½”. 
xxx 
 
On weekdays, I usually play video or computer 
games …. 
 hour(s) a day 
   
On weekends, I usually play video or computer 
games …. 
 hour(s) a day 
 
Items from survey cycle 21 questionnaire:  
 
14. In the past 12 months, how often did you …?  
 
Never 
Less than 
once a month 
1-3 times 
per month 
1-6 times 
per week 
Every 
day 
Use marijuana, 
cannabis, hashish                                                
         
 
15. How much do you weigh? 
      pounds         OR                 kilograms 
 
 
16. How tall are you without your shoes on? 
      feet       inches     OR            meters 
 
17. Check the box that describes you best…  
 I have smoked cigarettes, but not at all in the past 12 months  
 I smoked cigarettes once or a couple of times in the past 12 months 
 I smoke cigarettes once or a couple of times each month  
 I smoke cigarettes once or a couple of times each week  
 I smoke cigarettes every day  
 
18. On how many days did you smoke cigarettes, even just a puff during the 
last month, which was       (please type in month)? (for example, if this 
month is March, please answer the question for February) 
  None  Go to question 21 
  1 day      16-20 days  
  2-3 days      21-30 days  
  4-5 days       Every day  
  6-10 days     Don’t know 
  11-15 days  
xxxi 
 
 
19. On the days that you smoked during the last month, which was       
(please type in month), how many cigarettes did you usually smoke each 
day? (for example, if this month is March, please answer the question for 
February) 
   Less than 1 cigarette (one or a few puffs) 
   1 cigarette       16-20 cigarettes  
   2-3 cigarettes      21-25 cigarettes  
   4-5 cigarettes      More than 25  
   6-10 cigarettes     Don’t know  
   11-15 cigarettes  
 
20. On how many days did you smoke cigarettes, even just a puff during the 
month before the last, which was      (please type in month)? (for 
example, if this month is March, please answer the question for January)? 
   None   Go to question 23  
   1 day       16-20 days 
   2-3 days      21-30 days  
   4-5 days      Every day  
   6-10 days     Don’t know  
   11-15 days 
 
 
21. On the days that you smoked during the month before the last, which was 
      (please type in month), how many cigarettes did you usually smoke 
each day? (for example, if this month is March, please answer the 
question for January) 
   Less than 1 cigarette (one or a few puffs)  
   1 cigarette     16-20 cigarettes  
   2-3 cigarettes      21-25 cigarettes  
   4-5 cigarettes     More than 25  
   6-10 cigarettes    Don’t know  
   11-15 cigarettes   
 
22. On how many days did you smoke cigarettes, even just a puff during two 
months before the last, which was      (please type in month)? (for 
example, if this month is March, please answer the question for 
December)?  
   None  Go to question 25  
   1 day         16-20 days  
xxxii 
   2-3 days        21-30 days  
   4-5 days        Every day  
   6-10 days     Don’t know  
   11-15 days 
 
23. On the days that you smoked during two months before the last, which 
was       (please type in month), how many cigarettes did you usually 
smoke each day? (for example, if this month is March, please answer the 
question for December) 
   Less than 1 cigarette (one or a few puffs)  
   1 cigarette     16-20 cigarettes  
   2-3 cigarettes      21-25 cigarettes  
   4-5 cigarettes     More than 25 
   6-10 cigarettes    Don’t know 
   11-15 cigarettes  
 
 
24. Has a health professional ever diagnosed that you have any of the 
following? If yes, how old were you when first diagnosed? 
 
No Yes 
First 
diagnosed 
when I was…. 
Mood disorder (depression, bipolar 
disorder) 
    
      years old 
Anxiety disorder (phobia, fear of social 
situations, obsessive-compulsive disorder, 
panic disorder, generalized anxiety 
disorder)           
    
      years old 
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Appendix 2: Figures pertaining to the univariate and multivariate analyses  
Figure A.1: Mean change in waist circumference (cm) over seven years according to 
cannabis use in male participants, NDIT Study 2005-2012 
 
Figure A.2: Mean change in waist circumference (cm) over seven years according to 
cannabis use in female participants, NDIT Study 2005-2012 
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Figure A.3: Mean change in BMI (kg/m
2
) over seven years according to cannabis use in 
female participants, NDIT Study 2005-2012 
 
Figure A.4: Mean change in BMI (kg/m
2
) over seven years according to cannabis use in 
male participants, NDIT Study 2005-2012
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Figure A. 5: Predicted change in waist circumference (cm) (95% confidence interval) according to 
cannabis use in hypothetical male participants who smoke 0.5 and 15 cigarettes per day 
 
Figure A. 6: Likelihood ratio test: comparison of full and reduced regression models predicting change 
in BMI and WC in males 
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Appendix 3: Univariate analyses: extended tables 
Table A.I: Change in BMI (kg/m
2
) in male participants during young adulthood according to selected 
socio-demographic and lifestyle characteristics. NDIT Study, 2005-2012 
Characteristic 
BMI at age 21 
Mean (sd) 
BMI at age 25  
Mean (sd) 
Change BMI 
Mean (sd) 
p Value 
Age    0.168 
≤ 20.3 22.4(3.7) 24.3(3.8) 1.8(2.1)  
> 20.3 23.1(3.9) 25.3(4.3) 2.2(2.8)  
Language     0.730 
   French 23.1(4.3) 25.4(4.8) 2.1(2.3)  
   Other 22.6(3.6) 24.6(3.8) 2.0(2.6)  
Country of birth    0.064 
      Canada 22.8(3.9) 24.8(4.1) 1.9(2.4)  
       Other 22.0(2.3) 25.0(2.9) 3.0(3.1)  
Maternal education    0.699 
     No university  23.0(4.1) 25.0(4.1) 1.9(2.8)  
     Some university 22.6(3.6) 24.7(4.2) 2.1(2.2)  
Cannabis use     0.002 
      0 times/week 22.9(3.9) 25.5(4.4) 2.5(2.4)  
     0.1 times/week 22.5(2.9) 24.4(3.6) 1.9(2.2)  
     0.4 times/week 23.2(4.1) 23.9(3.2) 0.8(1.8)  
       3 times/week 22.1(4.5) 23.4(4.1) 1.3(3.3)  
       7 times/week 22.9(3.9) 24.0(3.6) 1.1(2.5)  
No. cigarette smoked/day    0.786 
 0 23.0(4.0) 25.2(4.1) 2.1(2.6)  
>0, ≤ 0.0822  21.8(2.7) 23.6(3.1) 1.8(2.3)  
>0.0822, ≤4.5  21.8(3.3) 23.6(3.4) 1.8(2.1)  
>4.5 23.9(4.2) 25.7(5.1) 1.8(2.7)  
Sedentary behavior    0.112 
≤ 3.6 hours/day 22.5(3.9) 24.8(3.7) 2.3(2.2)  
 > 3.6 hours/day 23.0(4.3) 24.9(4.5) 1.7(2.7)  
Physical activity    0.159 
≤ 9.5 times/week 22.8(4.1) 24.7(4.2) 1.8(2.4)  
 > 9.5 times/week 22.7(3.5) 24.9(4.0) 2.2(2.5)  
Depression symptom score    0.800 
≤ 1.75 22.8(3.8) 24.8(4.0) 2.0(2.7)  
 > 1.75 22.8(3.9) 24.8(4.2) 2.0(2.2)  
Alcohol use    0.261 
Non drinkers 23.3(4.2) 25.1(4.5) 1.7(2.7)  
      Occasional to weekly 22.5(3.7) 24.6(4.0) 2.1(2.4)  
      Weekly to daily 22.8(3.8) 24.8(4.1) 2.0(2.5)  
Notes: Age was categorized according to the mean. BMI was categorized based on normal weight, 
overweight and obese BMI categories. Waist circumference, sedentary behavior, physical activity and 
depression symptoms were categorized according to the median. Number of cigarettes per day was 
categorized according to tertile in smokers. Alcohol use was categorized according to past month 
frequency: 0 times/month non-drinkers, 0.1-7.9 times/month occasional to weekly, <8 times/month 
weekly/daily. 
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Table A.II: Change in BMI (kg/m
2
) in female participants during young adulthood according to 
selected socio-demographic and lifestyle characteristics. NDIT Study, 2005-2012 
Characteristic 
BMI at age 21 
Mean (sd) 
BMI at age 25  
Mean (sd) 
Change BMI 
Mean (sd) 
p Value 
Age    0.379 
≤ 20.3 21.6(3.3) 23.1(4.2) 1.4(2.3)  
> 20.3 22.9(4.6) 24.5(5.0) 1.6(2.7)  
Language     0.294 
   French 22.6(4.7) 24.3(5.4) 1.7(2.6)  
   Other 22.0(3.5) 23.4(4.2) 1.4(2.4)  
Country of birth    0.663 
      Canada 22.3(4.0) 23.8(4.7) 1.5(2.5)  
       Other 20.4(2.5) 22.1(2.5) 1.7(2.1)  
Maternal education    0.364 
     No university  22.2(3.9) 233.8(4.9) 1.6(2.4)  
     Some university 22.1(4.0) 23.4(4.0) 1.3(2.5)  
Cannabis use     0.036 
      0 times/week 22.2(3.6) 24.2(4.8) 1.8(2.6)  
     0.1 times/week 21.5(3.6) 22.6(3.2) 1.1(2.4)  
     0.4 times/week 22.1(3.7) 22.8(4.3) 0.7(1.6)  
       3 times/week 22.0(3.4) 22.8(4.2) 0.8(1.9)  
       7 times/week 23.5(7.6) 24.8(7.0) 1.3(2.9)  
No. cigarette smoked/day    .980 
 0 22.2(3.9) 3.8(4.8) 1.5(2.4)  
>0, ≤ 0.0822  22.0(3.2) 23.6(4.1) 1.5(2.2)  
>0.0822, ≤4.5  21.6(3.1) 23.0(4.0) 1.4(2.9)  
>4.5 22.8(5.8) 24.2(5.3) 1.4(2.7)  
Sedentary behavior    0.033 
≤ 2.9 hours/day 21.8(3.1) 23.0(3.6) 1.2(2.3)  
 > 2.9 hours/day 22.5(4.5) 24.3(5.4) 1.8(2.6)  
Physical activity    0.646 
≤ 7.5 times/week 22.1(4.4) 23.5(4.9) 1.4(2.3)  
 > 7.5 times/week 22.2(3.4) 23.8(4.4) 1.5(2.6)  
Depression symptom score    0.610 
≤ 2.45 22.2(4.0) 23.7(4.8) 1.5(2.5)  
 > 2.45 22.1(3.8) 23.6(4.4) 1.4(2.4)  
Alcohol use    0.977 
Non drinkers 22.4(4.2) 23.9(5.1) 1.5(2.6)  
      Occasional to weekly 21.9(3.7) 23.5(4.4) 1.5(2.4)  
      Weekly to daily 22.9(4.9) 24.3(4.5) 1.4(2.2)  
Notes: Age was categorized according to the mean. BMI was categorized based on normal weight, 
overweight and obese BMI categories. Waist circumference, sedentary behavior, physical activity and 
depression symptoms were categorized according to the median. Number of cigarettes per day was 
categorized according to tertile in smokers. Alcohol use was categorized according to past month 
frequency: 0 times/month non-drinkers, 0.1-7.9 times/month occasional to weekly, <8 times/month 
weekly/daily. 
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Table A.III:  Change in waist circumference (WC) (cm) in male participants during young adulthood 
according to selected socio-demographic and lifestyle characteristics. NDIT Study, 2005-2012 
Characteristic 
WC at age 21 
Mean (sd) 
WC at age 25 
Mean (sd) 
Change WC 
Mean (sd) 
p Value 
Age    0.217 
≤  20.3  79.2(9.9) 84.7(10.0) 5.2(6.8)  
> 20.3 80.5(8.7) 87.0(10.8) 6.4(7.7)  
Language     0.997 
   French 81.1(11.0) 86.7(12.4) 5.8(7.6)  
   Other 79.3(8.6) 85.5(9.7) 5.8(7.1)  
Country of birth    0.051 
   Canada 80.0(9.5) 85.8(10.6) 5.5(6.9)  
   Other      76.8(6.7) 85.8(8.6) 9.0(10.8)  
Maternal education    0.980 
     No university  80.3(10.6) 86.0(10.4) 5.8(7.8)  
     Some university 79.6(8.3) 86.0(10.6) 5.8(6.7)  
Cannabis use    0.066 
      0 times/week 80.0(9.3) 86.8(10.9) 6.9(7.3)  
     0.1 times/week 78.4(6.3) 84.5(9.2) 5.0(6.6)  
     0.4 times/week 80.5(10.7) 83.9(10.2) 2.6(3.9)  
     3 times/week 79.6(11.1) 83.9(10.9) 4.5(9.0)  
     7 times/week 81.1(11.6) 86.0(9.8) 5.0(7.3)  
No. cigarette smoked/day    0.648 
 0 80.3(9.7) 86.5(10.7) 5.9(7.4)  
>0, ≤ 0.0822  78.0(7.3) 83.9(8.2) 5.1(7.2)  
>0.0822, ≤4.5  77.5(7.0) 83.2(7.8) 4.9(5.0)  
>4.5 82.3(11.9) 88.6(12.9) 7.0(8.3)  
Sedentary behavior    0.239 
≤ 3.6 hours/day 78.9(7.6) 85.2(9.4) 6.4(6.8)  
 > 3.6 hours/day 80.7(10.7) 86.4(11.3) 5.3(7.6)  
Physical activity    0.501 
≤ 9.5 times/week 80.2(10.7) 85.7(10.8) 5.5(7.2)  
 > 9.5 times/week 79.4(7.8) 86.0(10.2) 6.1(7.3)  
Depression symptom score    0.654 
≤ 1.75 80.0(9.4) 85.6(10.6) 5.6(7.8)  
 > 1.75 80.0(9.4) 86.0(10.4) 6.0(6.7)  
Alcohol use    0.701 
Non drinkers 80.6(10.7) 86.5(11.6) 5.4(8.2)  
      Occasional to weekly 80.0(9.0) 85.6(9.7) 5.8(6.6)  
      Weekly to daily 77.3(5.9) 85.1(9.9) 6.6(6.7)  
Age was categorized by the mean of the cohort. BMI was categorized based on normal weight, 
overweight and obese BMI categories. Waist circumference, sedentary behavior, physical activity and 
depression symptoms were categorized based on the median. Number of cigarettes per day were split 
based on tertiles in smokers. Alcohol use was categorized according to past month frequency: 0 
times/month non-drinkers, 0.1-7.9times/month occasional to weekly, <8times/month weekly/daily. 
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Table A.IV: Change in waist circumference (WC) (cm) in female participants during young adulthood 
according to selected socio-demographic and lifestyle characteristics. NDIT Study, 2005-2012 
Characteristic 
WC at age 21 
Mean (sd) 
WC at age 25  
Mean (sd) 
Change WC 
Mean (sd) 
p Value 
Age    0.607 
≤  20.3  75.2(9.0) 76.7(10.6) 1.6(7.4)  
> 20.3 76.5(10.3) 78.9(12.2) 2.1(7.0)  
Language     0.013 
   French 76.6(11.3) 79.8(13.5) 3.4(8.1)  
   Other 75.4(8.8) 76.7(10.1) 1.1(6.7)  
Country of birth    0.358 
   Canada 76.1(9.7) 77.9(11.5) 1.7(7.3)  
   Other      69.9(6.1) 73.9(6.6) 3.5(6.5)  
Maternal education    0.210 
     No university  75.9(9.8) 78.0(12.4) 2.3(8.0)  
     Some university 76.0(9.6) 77.2(9.6) 1.2(6.3)  
Cannabis use    0.276 
      0 times/week 75.6(9.2) 78.1(11.8) 2.5(7.8)  
     0.1 times/week 75.4(9.4) 76.2(9.4) 0.9(6.2)  
     0.4 times/week 75.8(9.9) 76.5(11.8) 0.8(6.9)  
     3 times/week 77.1(9.0) 76.4(8.6) -0.1(6.6)  
     7 times/week 78.1(15.7) 81.2(15.7) 2.9(5.7)  
No. cigarette smoked/day    0.674 
 0 75.6(9.5) 77.4(11.4) 1.4(6.7)  
>0, ≤ 0.0822  76.9(8.7) 78.3(10.6) 2.2(7.1)  
>0.0822, ≤4.5  74.0(7.3) 76.8(10.9) 2.8(8.3)  
>4.5 77.4(13.3) 79.3(12.9) 2.1(8.5)  
Sedentary behavior    0.081 
≤ 2.9 hours/day 75.4(8.3) 76.3(9.5) 1.1(6.7)  
 > 2.9 hours/day 76.2(10.8) 78.9(12.8) 2.6(7.7)  
Physical activity    0.951 
≤ 7.5 times/week 75.6(10.6) 77.3(12.1) 1.8(7.1)  
 > 7.5 times/week 76.0(8.5) 78.0(10.4) 1.8(7.4)  
Depression symptom score    0.869 
≤ 2.45 76.1(9.9) 77.5(11.3) 1.7(7.4)  
 > 2.45 75.4(9.3) 77.7(11.4) 1.9(7.1)  
Alcohol use    0.771 
Non drinkers 76.0(10.2) 77.7(11.7) 2.3(7.3)  
      Occasional to weekly 75.4(8.9) 77.5(10.8) 1.7(6.7)  
      Weekly to daily 78.1(12.6) 78.7(13.9) 1.1(10.7)  
Age was categorized by the mean of the cohort. BMI was categorized based on normal weight, 
overweight and obese BMI categories. Waist circumference, sedentary behavior, physical activity and 
depression symptoms were categorized based on the median. Number of cigarettes per day were split 
based on tertiles in smokers. Alcohol use was categorized according to past month frequency: 0 
times/month non-drinkers, 0.1-7.9times/month occasional to weekly, <8times/month weekly/daily. 
 
